Document:

Exhibit 10.7

 

Metromile,
Inc.

 

 

 

February 11, 2021

 

Dan Preston

via email: dan@metromile.com

 

		Re:	Employment Terms

 

Dear Dan:

 

On behalf of Metromile,
Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in
this offer letter agreement (the “Agreement”). This Agreement shall become effective on the date that it is
signed by you (the “Effective Date”) and shall amend and restate any prior offer letter or employment agreement
between you and the Company, including your offer letter dated January 30, 2013.

 

		1.	Employment by the Company.

 

		(a)	Position. You will serve as the Company’s Chief Executive Officer. During the term
of your employment with the Company, you will devote your best efforts and substantially all of your business time and attention
to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted
by the Company’s general employment policies.

 

		(b)	Duties and Location. You will perform those duties and responsibilities as are customary
for the position of Chief Executive Officer and as may be directed by the Company’s Board of Directors (the “Board”),
to whom you will report. You will initially continue to work remotely; at such time as the Company reopens its offices in San Francisco,
California, that will be your primary office location. Notwithstanding the foregoing, the Company reserves the right to reasonably
require you to perform your duties at places other than your primary office location from time to time, and to require reasonable
business travel. The Company may modify your job title and duties as it deems necessary and appropriate in light of the Company’s
needs and interests from time to time.

 

		2.	Base Salary and Employee Benefits.

 

		(a)	Salary. You will be paid a base salary at the rate of $450,000 per year, less applicable
payroll deductions and withholdings. Your base salary will be paid on the Company’s ordinary payroll cycle. As an exempt
salaried employee, you will be required to work the Company’s normal business hours, and such additional time as appropriate
for your work assignments and position, and you will not be entitled to overtime compensation.

 

		(b)	Employee Benefits. As a regular full-time employee, you will continue to be eligible to
participate in the Company’s standard employee benefits offered to executive level employees, as in effect from time to time
and subject to the terms and conditions of the benefit plans and applicable Company policies. A full description of these benefits
is available upon request. The Company may change your compensation and benefits from time to time in its discretion.

 

		3.	Expenses. The Company will reimburse you for reasonable travel, entertainment or other expenses
incurred by you in furtherance of or in connection with the performance of your duties hereunder, in accordance with the Company’s
expense reimbursement policies and practices as in effect from time to time.

 

		4.	Equity Awards. The Board will recommend to the Board of Directors of INSU Acquisition Corp
II, a Delaware corporation (“Parent” and the “Parent Board”) that you be granted, as soon
as practicable following completion of the transactions contemplated by the Agreement and Plan of Merger and Reorganization by
and among Parent, INSU II Merger Sub Corp., a Delaware corporation, and the Company, dated as of November 24, 2020 (“Closing”),
the following Parent equity awards:

 

     

     

    

  

		(a)	Time-Based Restricted Stock Units. A restricted stock unit award covering 1,750,000 shares
of Parent common stock (“Time-Based RSUs”) under the Metromile, Inc. 2021 Equity Incentive Plan (the “Plan”).
Subject to approval by the Parent Board, the Time-Based RSUs shall be subject to a time-based vesting, with a vesting commencement
date of February 9, 2020 (the “Vesting Commencement Date”), and shall be satisfied quarterly over three (3)
years following the Vesting Commencement Date, with 145,833 of the shares vesting on each of the first eight completed calendar
quarters following the Vesting Commencement Date and 145,834 of the shares vesting on the ninth through twelfth completed calendar
quarters following the Vesting Commencement Date, in all cases subject to your continued employment with the Company or Parent
on each such vesting date.

 

		(b)	Performance-Based Restricted Stock Units. A restricted stock unit award covering 1,750,000
shares of the Parent common stock (as adjusted as set forth on Exhibit A to this Agreement) (the “Performance-Based
RSUs”). Subject to approval by the Parent Board, the Performance-Based RSUs shall be granted under the Plan, shall vest
as set forth on Exhibit A, and shall have a term of five years (from the grant date of such Performance-Based RSUs).

 

The Time-Based RSUs
and Performance-Based RSUs shall provide for an automatic sell-to-cover arrangement in respect of applicable withholding taxes
following the first release of shares from the Lockup (as defined on Exhibit A). Shares in respect of any vested portion of the
Time-Based RSUs and Performance-Based RSUs shall be delivered to you as soon as reasonably practicable following the applicable
vesting date but in no event later than two and one-half months after the end of the calendar year following the calendar year
in which such Time-Based RSUs or Performance-Based RSUs, as applicable, vest. The Time-Based RSUs and Performance-Based RSUs shall
also be subject to the provisions of the Plan and the applicable award agreement, provided, however, that the Company’s standard
forms shall be revised to provide that any clawbacks for RSUs adopted by the Company shall be limited to those required to comply
with the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.

 

In addition, outstanding
options to purchase 150,000 shares, granted on August 14, 2017, shall be deemed to have vested in full as of the Closing.

 

		5.	Compliance with Confidentiality Information Agreement and Company Policies. You acknowledge
and agree that your signed At-will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement that you
entered into with the Company (the “Confidentiality Agreement”) remains in full force and effect and binding
upon you. In addition, you are required to continue to abide by the Company’s policies and procedures (including but not
limited to the Company’s employee Handbook), as adopted or modified from time to time within the Company’s discretion,
and acknowledge in writing that you have read and will comply with such policies and procedures (and provide additional such acknowledgements
as such policies and procedures may be modified from time to time); provided, however, that in the event the terms
of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement
shall control.

 

		6.	Protection of Third Party Information. By signing this Agreement, you are representing that
you have full authority to accept this position and perform the duties of the position without conflict with any other obligations
and that you are not involved in any situation that might create, or appear to create, a conflict of interest with respect to your
loyalty to or duties for the Company. You specifically warrant that you are not subject to an employment agreement or restrictive
covenant preventing full performance of your duties to the Company. In addition, you agree not to bring to the Company or use in
the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally
available to the public, unless you have obtained express written authorization from the former employer for their possession and
use. You also agree to honor all obligations to former employers during your employment with the Company.

 

     

     

    

  

		7.	At-Will Employment Relationship. Your employment relationship with the Company will continue
to be at will. Accordingly, you may terminate your employment with the Company at any time and for any reason whatsoever simply
by notifying the Company; and the Company may terminate your employment at any time, with or without Cause or advance notice.

 

		8.	Severance in the Event of Qualifying Termination Absent a Change of Control. If, at any
time, the Company terminates your employment without Cause (other than as a result of your death or disability) or you resign for
Good Reason (either such termination referred to as a “Qualifying Termination”), provided such termination or
resignation constitutes a Separation from Service (as defined under Treasury Regulation Section 1.409A-1(h), without regard to
any alternative definition thereunder, a “Separation from Service”), then subject to Sections 10 (“Limitation
on Severance Benefits / Clawback and Recovery”), 11 (“Conditions to Receipt of Severance Benefits and Accelerated
Vesting”) and 12 (“Return of Company Property”) below and your continued compliance with the terms of this Agreement
(including without limitation the Confidentiality Agreement), the Company will provide you with the following severance benefits
(the “Non-CIC Severance Benefits”):

 

		(a)	Cash Severance. The Company will pay you, as cash severance, twelve (12) months of your
base salary in effect as of your Separation from Service date, less standard payroll deductions and tax withholdings (the “Severance”).
The Severance will be paid in installments in the form of continuation of your base salary payments, paid on the Company’s
ordinary payroll dates, commencing on the Company’s first regular payroll date that is more than sixty (60) days following
your Separation from Service date, and shall be for any accrued base salary for the sixty (60)-day period plus the period from
the sixtieth (60th) day until the regular payroll date, if applicable, and all salary continuation payments thereafter,
if any, shall be made on the Company’s regular payroll dates.

 

		(b)	COBRA Severance. The Company will continue to pay the cost of your health care coverage
in effect at the time of your Separation from Service for a maximum of twelve (12) months, either by reimbursing you for or paying
directly (at the Company’s discretion) your COBRA premiums to continue such coverage (the “COBRA Severance”).
The Company's obligation to pay the COBRA Severance on your behalf will cease if you obtain health care coverage from another source
(e.g., a new employer or spouse’s benefit plan), unless otherwise prohibited by applicable law. You must notify the Company
within two (2) weeks if you obtain coverage from a new source. This payment of COBRA Severance by the Company would not expand
or extend the maximum period of COBRA coverage to which you would otherwise be entitled under applicable law. Notwithstanding the
above, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA Severance without potentially
violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu
thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to
pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium
for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether you elect
COBRA continuation coverage and shall end on the earlier of (x) the date upon which you obtain other coverage or (y) the last day
of the twelfth (12th) calendar month following your Separation from Service date.

 

		9.	Severance in the Event of Qualifying Termination in Connection with a Change of Control.
In the event of a Qualifying Termination that occurs within three (3) months prior to or within twelve (12) months following the
closing of a Change of Control (as defined below), provided such Qualifying Termination constitutes a Separation from Service,
then subject to Sections 10 (“Limitation on Severance Benefits / Clawback and Recovery”), 11 (“Conditions
to Receipt of Severance Benefits and Accelerated Vesting”) and 12 (“Return of Company Property”) below and your
continued compliance with the terms of this Agreement (including without limitation the Confidentiality Agreement), then the Company
will provide you with the following severance benefits (the “CIC Severance Benefits”): (i) the Severance in
the form and as set forth in Section 8(a) above, except that such Severance will be extended from twelve (12) months to eighteen
(18) months; (ii) the COBRA Severance, in the form and as set forth in Section 8(b) above, except that such COBRA Severance will
be extended from twelve (12) months to eighteen (18) months; and (iii) the Company shall accelerate the vesting of any then-unvested
Time-Based RSUs such that one hundred percent (100%) of such shares shall be deemed satisfied as of your Separation from Service
date (the “Accelerated Vesting”).

 

     

     

    

  

		10.	Limitation on Severance Benefits / Clawback and Recovery. Under no circumstances will you
be able to receive both the Non-CIC Severance Benefits and the CIC Severance Benefits. Any and all Non-CIC Severance Benefits and
CIC Severance Benefits provided under this Agreement will be subject to recoupment in accordance with any clawback policy that
the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which
the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection
Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions as the Board
determines necessary to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law, including
but not limited to a reacquisition right in respect of previously acquired shares of common stock of the Company or other cash
or property upon the occurrence of a termination of employment for Cause.

 

		11.	Resignation Without Good Reason; Termination for Cause; Death or Disability. If, at any
time, you resign your employment without Good Reason, or the Company terminates your employment for Cause, or if either party terminates
your employment as a result of your death or disability, you will receive your base salary accrued through your last day of employment,
as well as any unused vacation (if applicable) accrued through your last day of employment. Under these circumstances, you will
not be entitled to any other form of compensation from the Company, including any Non-CIC Severance Benefits, CIC Severance Benefits,
or Accelerated Vesting, as applicable, , other than your rights to the vested portion of your Option and any other rights to which
you are entitled under the Company’s benefit programs.

 

		12.	Conditions to Receipt of Severance Benefits and Accelerated Vesting. Prior to and as a condition
to your receipt of the Non-CIC Severance Benefits, the CIC Severance Benefits, or the Accelerated Vesting, you shall execute and
deliver to the Company an effective release of claims in favor of and in a form acceptable to the Company (the “Release”)
within the timeframe set forth therein, but not later than forty-five (45) days following your Separation from Service date, and
allow the Release to become effective according to its terms (by not invoking any legal right to revoke it) within any applicable
time period set forth therein (such latest permitted effective date, the “Release Deadline”).

 

     

     

    

  

		13.	Return of Company Property. Upon the termination of your employment for any reason, as a
precondition to your receipt of the Non-CIC Severance Benefits, the CIC Severance Benefits, and the Accelerated Vesting, as applicable
(if and as applicable), within five (5) days after your Separation from Service Date (or earlier if requested by the Company),
you must return to the Company all Company documents (and all copies thereof) and other Company property in your possession, custody
or control, including, but not limited to, Company files, notes, financial and operational information, password and account information,
customer lists and contact information, prospect information, product and services information, research and development information,
drawings, records, plans, forecasts, pipeline reports, sales reports or other reports, payroll information, spreadsheets, studies,
analyses, compilations of data, proposals, agreements, sales and marketing information, personnel information, specifications,
code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers,
facsimile machines, mobile telephones, tablets, handheld devices, and servers), credit cards, entry cards, identification badges
and keys, and any materials of any kind which contain or embody any proprietary or confidential information of the Company, and
all reproductions thereof in whole or in part and in any medium. You further agree that you will make a diligent search to locate
any such documents, property and information and return them to the Company within the timeframe provided above. You also must
provide the Company all passwords, log-ins, administrative access, and any other information or access for and relating to any
Company computer or other device that you have used to access or use the Company’s network, as well as any Company database
or Company accounts with third parties which you established, administered, or to which you had access, and must terminate your
access to such network and accounts and otherwise comply with any Company requests regarding all such access and accounts. In addition,
if you have used any personal computer, server, or email system to receive, store, review, prepare or transmit any confidential
or proprietary data, materials or information of the Company, then within five (5) days after your Separation from Service date
(or earlier if requested by the Company) you must provide the Company with a computer-useable copy of such information and permanently
delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole
or in part); and you agree to provide the Company access to your system, as requested, to verify that the necessary copying and
deletion is done. If requested, you shall deliver to the Company a signed statement certifying compliance with this Section prior
to the receipt of the Non-CIC Severance Benefits, the CIC Severance Benefits, or the Accelerated Vesting, as applicable.

 

		14.	Outside Activities. Throughout your employment with the Company, you may engage in civic
and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or present
a conflict of interest with the Company. During your employment by the Company, except on behalf of the Company, you will not directly
or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative
or consultant of any other person, corporation, firm, partnership or other entity whatsoever known by you to compete with the Company
(or is planning or preparing to compete with the Company), anywhere in the world, in any line of business engaged in (or planned
to be engaged in) by the Company; provided, however, that you may purchase or otherwise acquire up to (but not more than) one percent
(1%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities
are listed on any national or regional securities exchange.

 

		15.	Definitions. For purposes of this Agreement, the following terms shall have the following
meanings:

 

“Cause”
for termination will mean your: (a) commission or conviction (including a guilty plea or plea of nolo contendere) of any felony
or any other crime involving fraud, dishonesty or moral turpitude; (b) commission or attempted commission of or participation in
a fraud or act of dishonesty or misrepresentation against the Company; (c) material breach of your duties to the Company; (d) intentional
damage to any property of the Company causing material harm to the Company; (e) gross misconduct, or other material violation of
Company policy that causes, or reasonably could be anticipated to cause, harm; (f) material violation of any written and fully
executed contract or agreement between you and the Company, including without limitation, material breach of your Confidentiality
Agreement, or of any Company policy, or of any statutory duty you owe to the Company; or (g) conduct which in the good faith and
reasonable determination of the Company demonstrates gross unfitness to serve. The determination that a termination is for Cause
shall be made by the Company in its sole discretion.

 

     

     

    

  

You shall have “Good
Reason” for resigning from employment with the Company if any of the following actions are taken by the Company without
your prior written consent: (a) a material reduction in your base salary, which the parties agree is a reduction of at
least 25% of your base salary (unless pursuant to a salary reduction program applicable generally to the Company’s similarly
situated employees); (b) a material reduction in your duties (including responsibilities and/or authorities), provided, however,
that a change in job position (including a change in title) shall not be deemed a “material reduction” in and of itself
unless your new duties are materially reduced from the prior duties; or (c) relocation of your principal place of employment to
a place that increases your one-way commute by more than fifty (50) miles as compared to your then-current principal place of employment
immediately prior to such relocation. In order to resign for Good Reason, you must provide written notice to the Board within 30
days after the first occurrence of the event giving rise to Good Reason setting forth the basis for your resignation, allow the
Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within
such period, you must resign from all positions you then hold with the Company not later than 30 days after the expiration of the
cure period.

 

“Change of
Control” shall have the meaning set forth in the Plan.

 

		16.	Compliance with Section 409A. It is intended that the Non-CIC
Severance Benefits, the CIC Severance Benefits, and the Accelerated Vesting, as applicable, satisfy, to the greatest extent possible,
the exemptions from the application of Section 409A of the Internal Revenue Code of 1986, as amended, (the “Code”)
(Section 409A, together with any state law of similar effect, “Section 409A”) provided under Treasury Regulations
1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). For purposes of Section 409A (including, without limitation, for purposes of
Treasury Regulations 1.409A-2(b)(2)(iii)), your right to receive any installment payments under this Agreement (whether severance
payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each
installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to
the contrary in this Agreement, if the Company (or, if applicable, the successor entity thereto) determines that the Non-CIC Severance
Benefits, the CIC Severance Benefits, and the Accelerated Vesting, as applicable, constitute “deferred compensation”
under Section 409A and you are, on the date of your Separation from Service, a “specified employee” of the Company
or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code (a “Specified Employee”),
then, solely to the extent necessary to avoid the incurrence of adverse personal tax consequences under Section 409A, the timing
of the Non-CIC Severance Benefits, the CIC Severance Benefits, and the Accelerated Vesting, as applicable, shall be delayed until
the earliest of: (i) the date that is six (6) months and one (1) day after your Separation from Service date, (ii) the date
of your death, or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the
first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments or benefits deferred
pursuant to this Section shall be paid in a lump sum or provided in full by the Company (or the successor entity thereto, as applicable),
and any remaining payments due shall be paid as otherwise provided herein. No interest shall be due on any amounts so deferred.
If the Non-CIC Severance Benefits, the CIC Severance Benefits, or the Accelerated Vesting, as applicable, are not covered by one
or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the
calendar year in which you have a Separation from Service, the Release will not be deemed effective any earlier than the Release
Deadline. The Non-CIC Severance Benefits, the CIC Severance Benefits, and the Accelerated Vesting, as applicable, Non-CIC Severance
Benefits, the CIC Severance Benefits, and the Accelerated Vesting, as applicable, are intended to qualify for an exemption from
application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences
under Section 409A, and any ambiguities herein shall be interpreted accordingly. Notwithstanding
anything to the contrary herein, to the extent required to comply with Section 409A, a termination of employment shall not be deemed
to have occurred for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following
a termination of employment unless such termination is also a “separation from service” within the meaning of Section
409A.  With respect to reimbursements or in-kind benefits provided to you hereunder (or otherwise) that are not exempt from
Section 409A, the following rules shall apply: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided,
during any one of your taxable years shall not affect the expenses eligible for reimbursement, or in-kind benefit to be provided
in any other taxable year, (ii) in the case of any reimbursements of eligible expenses, reimbursement shall be made on or before
the last day of your taxable year following the taxable year in which the expense was incurred, (iii) the right to reimbursement
or in-kind benefits shall not be subject to liquidation or exchange for another benefit.

 

     

     

    

  

		17.	Section 280G; Parachute Payments.

 

		(a)	If any payment or benefit you will or may receive from the Company or otherwise (a “280G
Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code,
and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”),
then any such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount.
The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the
Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment,
whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal,
state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results
in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment
may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount
is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction
Method”) that results in the greatest economic benefit for you. If more than one method of reduction will result in the
same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).

 

		(b)	Notwithstanding any provision of subsection (a) above to the contrary, if the Reduction Method
or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that
would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method,
as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first
priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined
on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without
Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority,
Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before
Payments that are not deferred compensation within the meaning of Section 409A.

 

		(c)	Unless you and the Company agree on an alternative accounting firm or law firm, the accounting
firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change of Control
transaction shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant
or auditor for the individual, entity or group effecting the change of control transaction, the Company shall appoint a nationally
recognized accounting or law firm to make the determinations required by this Section 17 (“Section 280G; Parachute Payments”).
The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.
The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder
to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar
days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you
or the Company) or such other time as requested by you or the Company.

 

		(d)	If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of
Section 17(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise
Tax, you agree to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of
Section 17(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced
Amount was determined pursuant to clause (y) of Section 17(a), you shall have no obligation to return any portion of the Payment
pursuant to the preceding sentence.

 

     

     

    

  

		18.	Dispute Resolution. To ensure the rapid and economical resolution of disputes that may arise
in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of
action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance,
or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved
pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent permitted by law, by final, binding and confidential
arbitration conducted by JAMS, Inc. or its successor (“JAMS”), under JAMS’ then applicable rules
and procedures for employment disputes before a single arbitrator (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/).
You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such
dispute through a trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action
under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff
(or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of
any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside
over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings
are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class
shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be
subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private
Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor
Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such
applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the “Excluded
Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the
Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration. You will
have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration
under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear
on the final disposition are also matters for the arbitrator. The arbitrator shall: (a) have the authority to compel adequate discovery
for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement
signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons
for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall
be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all
JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court
of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court
to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered
and enforced as judgments in the federal and state courts of any competent jurisdiction.

 

		19.	Miscellaneous. This Agreement, together with your Confidentiality Agreement, forms the complete
and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you
by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the Company’s
or the Board’s discretion in this Agreement, require a written modification approved by the Company and signed by a duly
authorized officer of the Company (other than you). This Agreement will bind the heirs, personal representatives, successors and
assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.
If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall
not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable
in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement shall be construed
and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Any ambiguity
in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights
hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement
may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S.
federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall
be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.

 

     

     

    

  

Please sign and date
this Agreement and return it to me on or before February 12, 2021 if you wish to accept continued employment at the Company under
the terms described above. The offer of continued employment herein will expire if I do not receive this signed letter by that
date. I would be happy to discuss any questions that you may have about these terms.

 

	Sincerely,	 	 
	 	 	 	 
	/s/ Dave Friedberg	 	 	 
	Dave Friedberg, Founder & Executive Chairman	 	 
	 	 	 	 
	 	 	 	 
	Reviewed, Understood, and Accepted:	 	 
	 	 	 	 
	/s/ Dan Preston	 	2/11/21	 
	Dan Preston	 	Date	 

 

Exhibit A: Performance-Based
RSU Terms

 

     

     

    

 

 

Exhibit
A

 

Performance-Based
RSU Terms

 

The terms below shall
apply to your Performance-Based RSUs subject to your Continuous Service (as defined in the Plan) through the applicable vesting
date:

 

1) 291,667 of the
Performance-Based RSUs shall vest upon the date on which the Company first achieves an active number of “policies in force”
greater than or equal to 250,000, as determined by the Board in its sole discretion.

 

2) 291,667 of the
Performance-Based RSUs shall vest upon the date on which the Company first achieves an active number of “policies in force”
greater than or equal to 500,000, as determined by the Board in its sole discretion.

 

3) 583,333 of the
Performance-Based RSUs shall vest upon the date on which the Company first achieves a positive operating cashflow (excluding marketing
expenses, device expenses, new business underwriting expenses and reinsurance expenses) for a period of at least one financial
quarter, as determined by the Board in its sole discretion.

 

4) 583,333 of the
Performance-Based RSUs shall vest upon the achievement of a $25 per share price of the Parent Common Stock over any twenty (20)
Trading Days within any thirty (30) Trading Day (the “Share-Based Milestone”). Notwithstanding the foregoing,
the Share-Based Milestone shall be deemed satisfied as set forth in the table below in connection with a Change of Control (as
defined in the Plan) that occurs prior to February 15, 2025. Price per share shall be the value paid for all of the shares of each
class of Parent common stock or any successor entity in connection with a Change of Control. In the event of a stock-for-stock
acquisition, the value of the acquiror’s shares shall be valued based on the volume weighted average closing price over the
60-day period ending on and including the trading day occurring on the day prior to consummation of such Change of Control.

 

	Price per share	Percentage of Performance-Based RSUs Subject to the Share-Based Milestone Vesting
	At least $25 but less than $30	33%
	At least $30 but less than $35	66%
	At least $35	100%

 

If the Share-Based
Milestone is not met on or before February 15, 2025, all Performance-Based RSUs that are subject to the Share-Based Milestone will
be forfeited. In the event of a Change of Control, the vesting conditions for all Performance-Based RSUs, other than the Performance-Based
RSUs subject to the Share-Based Milestone (which shall vest in accordance with (4) above), shall be deemed to have been achieved
as of the closing of such Change of Control in the proportion set forth in the table above (e.g. if the price per share is less
than $25, none of the Performance-Based RSUs shall be deemed to have been achieved, if the price per share is $35 or more, all
of the Performance-Based RSUs shall be deemed to have been achieved etc.).

 

Notwithstanding anything
in this Exhibit A to the contrary, if vesting conditions for Performance-Based RSUs are otherwise met prior to the first release
of shares from any lockup agreement restricting shares following Closing (the “Lockup”), the Performance-Based
RSUs will not vest until following the first release of shares from the Lockup.

 

Any of the share amounts
and share prices for Performance-Based RSUs shall be automatically adjusted in the event of stock splits, any extraordinary dividend
or other extraordinary distribution, combinations and the like occurring prior to the date of grant.Document

Exhibit 10.6

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BETWEEN
VERTEX PHARMACEUTICALS INCORPORATED
VERTEX PHARMACEUTICALS (EUROPE) LIMITED
AND
CRISPR THERAPEUTICS AG
CRISPR THERAPEUTICS LIMITED
CRISPR THERAPEUTICS, INC.
TRACR HEMATOLOGY LTD.

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

TABLE OF CONTENTS
Page
						
	ARTICLE 1 DEFINITIONS
	2

	ARTICLE 2 GOVERNANCE
	15

	2.1.    Joint Steering Committee
	15

	2.2.    Joint Research Committee
	17

	2.3.    Joint Development Committee
	18

	2.4.    Joint Commercialization Committee
	20

	2.5.    Joint Manufacturing Committee
	22

	2.6.    Alliance Managers
	24

	2.7.    Other Committees
	25

	2.8.    Decision-Making
	25

	ARTICLE 3 Development
	26

	3.1.    Research and Development Plans
	26

	3.2.    Project Team
	27

	3.3.    Development Activities
	28

	3.4.    Diligence
	37

	3.5.    Follow-On Products
	37

	3.6.    Additional [***] Targets
	37

	ARTICLE 4 Medical Affairs Activities.
	38

	ARTICLE 5 Commercialization.
	38

	5.1.    Responsibilities
	38

	5.2.    Commercialization Plans
	38

	5.3.    Elements of Global Commercialization Plan
	39

	5.4.    Commercialization Activities
	40

	5.5.    Diligence
	40

	ARTICLE 6 Manufacturing
	41

	6.1.    Manufacturing Diligence
	41

	6.2.    Manufacturing Working Group
	41

	6.3.    Responsibilities
	43

	6.4.    Sharing of Manufacturing Information
	43

	6.5.    CMO Agreements
	44

	ARTICLE 7 FINANCIAL TERMS; Allocation of Net Profit and Net Loss
	44

	7.1.    Upfront Payments
	44

	7.3.    Allocation
	44

	7.4.    Calculation
	44

	7.5.    Payment of Expenses; Summary Statements
	44

	7.6.    Reconciliation
	45

	7.7.    Cost Overruns
	46

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

						
	7.8.    Books and Records
	46

	7.9.    Payment Method; Currency
	47

	7.10.    Late Payment
	47

	7.11.    Payments To / From CRISPR Entities
	47

	ARTICLE 8 Adverse Events
	47

	8.1.    Pharmacovigilance Agreement
	47

	8.2.    Global Safety Database
	48

	8.3.    Risk Management and Signal Detection Activities
	48

	8.4.    Access to Safety Information
	48

	ARTICLE 9 Subcontracting
	48

	ARTICLE 10 LICENSE GRANTS
	49

	10.1.    Acknowledgment of Option Exercise
	49

	10.2.    License Grants to Vertex
	49

	10.3.    License Grants to CRISPR
	50

	10.4.    Licenses to Improvements
	50

	10.5.    Sublicensing
	51

	10.6.    No Implied Licenses
	51

	10.7.    Third Party Agreements
	52

	10.8.    Trademarks
	53

	ARTICLE 11 INTELLECTUAL PROPERTY
	53

	ARTICLE 12 REPRESENTATIONS AND WARRANTIES
	53

	12.1.    Representations and Warranties of Vertex
	53

	12.2.    Representations and Warranties of CRISPR
	54

	12.3.    CRISPR Covenants
	56

	12.4.    Vertex Covenants
	57

	12.5.    Disclaimer
	57

	12.6.    [***]
	58

	ARTICLE 13 INDEMNIFICATION; INSURANCE
	58

	13.1.    Indemnification by Vertex
	58

	13.2.    Indemnification by CRISPR
	58

	13.3.    Procedure
	59

	13.4.    Other Third Party Claims
	59

	13.5.    Insurance
	60

	13.6.    Limitation of Consequential Damages
	61

	ARTICLE 14 TERM; TERMINATION
	61

	14.1.    Co-Co Agreement Term; Expiration
	61

	14.2.    Termination of the Agreement
	61

	14.3.    Opt-Out
	65

	14.4.    Consequences of Expiration or Certain Terminations of the Agreement
	68

	14.5.    Alternative Remedies for Material Breach
	69

	14.6.    Survival
	69

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

						
	ARTICLE 15 CONFIDENTIALITY
	69

	ARTICLE 16 MISCELLANEOUS
	70

	16.1.    Assignment
	70

	16.2.    Change of Control
	70

	16.3.    Force Majeure
	71

	16.4.    Representation by Legal Counsel
	71

	16.5.    Notices
	71

	16.6.    Amendment
	73

	16.7.    Waiver
	73

	16.8.    Severability
	73

	16.9.    Descriptive Headings
	73

	16.10.    Export Control
	73

	16.11.    Governing Law
	73

	16.12.    Entire Agreement
	74

	16.13.    Independent Contractors
	74

	16.14.    Interpretation
	74

	16.15.    No Third Party Rights or Obligations
	74

	16.16.    Further Actions
	75

	16.17.    Counterparts
	75

	16.18.    CRISPR Entities
	75

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of December 12, 2017 (the “Effective Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales (“CRISPR UK”), and TRACR Hematology Ltd, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK, CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.”
RECITALS
WHEREAS, the Parties and certain of their Affiliates (as defined below) have entered into that certain Strategic Collaboration, Option and License Agreement dated as of October 26, 2015, as amended by that certain Amendment No. 1 by and between the Parties dated as of the Effective Date (the “Collaboration Agreement”);
WHEREAS, pursuant to the Collaboration Agreement, Vertex and CRISPR are conducting a strategic collaboration focused on exploring potential targets related to certain diseases and creating therapeutics using gene editing [***], including the CRISPR/Cas System, to treat such diseases, including the Products (as defined below);
WHEREAS, pursuant to Section 4.1.1 of the Collaboration Agreement, Vertex has obtained an Option (as defined therein) with respect to [***], and the execution of this Agreement constitutes the exercise by Vertex of the Option with respect to [***] that becomes a Collaboration Target;
WHEREAS, the Parties agree that [***] under the Collaboration Agreement; and
WHEREAS, the Parties desire to enter into this Agreement in accordance with Section 6.1.2(c) of the Collaboration Agreement in order for the Parties to jointly develop and commercialize the Shared Products and to conduct additional research with respect to the Follow-On Products (as defined below).
NOW, THEREFORE, in consideration of the respective covenants, representations, warranties and agreements set forth herein, the Parties hereto agree as follows:
ARTICLE 1
DEFINITIONS
1

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

For purposes of this Agreement, the following capitalized terms will have the meanings set forth in this ARTICLE 1.  Capitalized terms used but not defined herein will have their respective meanings set forth in the Collaboration Agreement. 
1.1.    “Agreement” has the meaning set forth in the Preamble.
1.2.    “Alliance Manager” has the meaning set forth in Section 2.6.1.
1.3.    “[***] Arbitration” means [***] style arbitration in accordance with the arbitration procedure set forth on Schedule A.
1.4.    [***].
1.5.    [***]. 
1.6.    “[***] Third Party Agreement” has the meaning set forth in Section 10.7.2.
1.7.    [***].
1.8.    [***].
1.9.    “Calendar Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 or December 31, during the Co-Co Agreement Term, or the applicable part thereof during the first or last calendar quarter of the Co-Co Agreement Term.
1.10.    “Calendar Year” means any calendar year ending on December 31, or the applicable part thereof during the first or last year of the Co-Co Agreement Term.
1.11.    “Challenging Party” has the meaning set forth in Section 14.2.3.
1.12.    “Clinical Operations Study Lead” has the meaning set forth in Section 3.2.2.
1.13.    “CMO” means contract manufacturing organization. 
1.14.    “CRO” means contract research organization.
1.15.    “Co-Co Agreement Term” means the period commencing on the Effective Date and ending on the expiration of this Agreement pursuant to Section 14.1, unless terminated earlier as provided herein.
1.16.    “Collaboration Agreement” has the meaning set forth in the Recitals.
1.17.    “Combination Product” has the meaning set forth in Section 1.82.
1.18.    “Commercialization Costs” [***]: 
1.18.1.    [***];
2

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.18.2.    [***];
1.18.3.    [***]; 
1.18.4.    [***];
1.18.5.    [***];
1.18.6.    [***];
1.18.7.    [***];
1.18.8.    [***]
1.18.9.    [***].
Commercialization Costs will exclude all of the payments set forth in Section 7.1 of the Collaboration Agreement, Research Costs, Development Costs, Manufacturing Costs, Medical Affairs Costs, Quality Costs, Other Out-of-Pocket Costs and Expenses attributable to general corporate activities, executive management, investor relations, treasury services, business development, corporate government relations, external financial reporting and other overhead activities.
1.19.    “Competitive Program” has the meaning set forth in Section 1.20.
1.20.    “Competitor” means any pharmaceutical company that is conducting a research, development or commercial program for a product that is intended to (a) [***], (b) [***] or (c) [***] (each of (a)-(c), a “Competitive Program”) [***].
1.21.    “CRISPR” has the meaning set forth in the Preamble.
1.22.    “CRISPR Background Know-How” means any Know-How, other than Joint Program Know-How and CRISPR Program Know-How, that (a) [***] and (b) [***].
1.23.    “CRISPR Background Patents” means any Patent, other than a Joint Program Patent, CRISPR Program Patent or CRISPR Platform Technology Patent that (a) [***] and (b) [***].
1.24.    “CRISPR In-License Agreements” means CRISPR’s or its Affiliates’ agreements with Third Party licensors or sellers listed on Schedule E, which Schedule shall be updated upon the designation of any Follow-On Product as a Shared Product under this Agreement, to include any agreements pursuant to which CRISPR or its Affiliates have in-licensed or acquired any Licensed CRISPR Technology with respect to such Shared Product. 
3

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.25.    “CTA” means a clinical trial application submitted to a Regulatory Authority, the submission and approval of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in the jurisdiction of such Regulatory Authority.
1.26.    “Development Budget” has the meaning set forth in Section 3.1.1.
1.27.    “Development Costs” [***]:
1.27.1.    [***];
1.27.2.    [***];
1.27.3.    [***];
1.27.4.    [***]; 
1.27.5.    [***];
1.27.6.    [***].
[***].
1.28.    “Distributor” means a Third Party to whom either Party grants a right to sell or distribute a Shared Product, which Third Party does not make payments to the granting Party that are calculated on the basis of a percentage of, or profit share on, such Third Party’s sales of Shared Products.
1.29.    “Dollar” means the United States Dollar. 
1.30.    “Effective Date” has the meaning set forth in the Preamble. 
1.31.    “Exclusive License” has the meaning set forth in Section 10.2.1.
1.32.    “Executive Officers” means the Chief Executive Officer of CRISPR, initially Samarth Kulkarni, and the Chief Operating Officer of Vertex, initially Ian Smith. 
1.33.    “Expenses” means Out-of-Pocket Costs and FTE Costs.
1.34.    “Follow-On Agent” means a product comprising (a) [***], or (b) [***].
1.35.    “Follow-On Product” means any pharmaceutical product, medical therapy, preparation, substance, or formulation comprising or employing, in whole or in part, a Follow-On Agent, but excluding the Initial Shared Product.
1.36.    “Follow-On Research Plan” has the meaning set forth in Section 3.1.2.
4

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.37.    “FTE” means one employee full-time for one year or more than one person working the equivalent of a full-time person, working directly on performing activities under the Global Development Plan, the Follow-On Research Plan, the Medical Affairs Plan, the Manufacturing Plan, the Quality Agreement, any Global Commercialization Plan or any Regional Commercialization Plan, as applicable, where “full-time” is considered [***] hours for one Calendar Year. No additional payment will be made with respect to any individual who works more than [***] hours per Calendar Year and any individual who devotes less than [***] hours per Calendar Year will be treated as an FTE on a pro rata basis based upon the actual number of hours worked divided by [***].
1.38.    “FTE Costs” means the product of (a) the number of FTEs (proportionately, on a per-FTE basis) used by a Party or its Affiliates in directly performing activities assigned to such Party under and in accordance with the Global Development Plan, the Follow-On Research Plan, the Medical Affairs Plan, the Manufacturing Plan, the Quality Agreement, any Global Commercialization Plan or any Regional Commercialization Plan, as applicable, and (b) the FTE Rate.
1.39.    “Global Brand Strategy” has the meaning set forth in Section 5.3.1.
1.40.    “Global Commercialization Budget” has the meaning set forth in Section 5.2.
1.41.    “Global Commercialization Plan” has the meaning set forth in Section 5.2.
1.42.    “Global Communication Strategy” has the meaning set forth in Section 5.3.2. 
1.43.    “Global Development Plan” has the meaning set forth in Section 3.1.1.
1.44.    “Global Manufacturing Plan” has the meaning set forth in Section 6.2.
1.45.    “Global Market Access and Value Strategy” has the meaning set forth in Section 5.3.3.
1.46.    “Global Pricing Strategy” has the meaning set forth in Section 5.3.4.
1.47.    “Global Safety Database” has the meaning set forth in Section 8.2.
1.48.    [***].
1.49.    [***].
1.50.    [***]. 
1.51.    “ICH” means The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
5

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.52.    “[***] Agreement” means [***], as originally executed and as the same may be amended, restated or modified from time to time in accordance with its terms. 
1.53.    “IND Transfer Date” has the meaning set forth in Section 3.3.1(b).
1.54.    “Initial Clinical Trials” means the first-in-human study of the Initial Shared Product in subjects with beta-thalassemia and the first-in-human study of the Initial Shared Product in subjects with sickle cell disease. 
1.55.    “Initial Shared Product” means the [***].
1.56.    “Integrated Budget” means the annual overall budget for activities performed under this Agreement, which shall include the amounts set forth in each of the Research Budget, the Development Budget, the Global Commercialization Budget, the Medical Affairs Budget and the Manufacturing Budget for the applicable Calendar Year.
1.57.    “JCC” has the meaning set forth in Section 2.4.1.
1.58.    “JDC” has the meaning set forth in Section 2.3.1.
1.59.    “JMC” has the meaning set forth in Section 2.5.1.
1.60.    “JSC” has the meaning set forth in Section 2.1.1.
1.61.    “Knowledge” means the [***] of [***] after [***].
1.62.    “Lead Commercialization Party” has the meaning set forth in Section 5.1.
1.63.    “Licensed CRISPR Know-How” means (a) CRISPR Background Know-How, (b) CRISPR Program Know-How and (c) CRISPR’s interest in the Joint Program Know-How.
1.64.    “Licensed CRISPR Patents” means (a) CRISPR Background Patents, (b) CRISPR Platform Technology Patents, (c) CRISPR Program Patents and (d) CRISPR’s interest in the Joint Program Patents.
1.65.    “Licensed CRISPR Technology” means, subject to Section 10.2.3 and Section 10.7.2, any and all Licensed CRISPR Patents and Licensed CRISPR Know-How.
1.66.    “Licensed Vertex Know-How” means (a) any [***], that (i) [***] and (ii) [***], (b) [***] and (c) the [***]. 
1.67.    “Licensed Vertex Patents” means (a) [***] that (i) [***] and (ii) [***], (b) the [***] and (c) the [***].
6

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.68.    “Licensed Vertex Technology” means, subject to Section 10.3.3 and Section 10.7.2, any and all Licensed Vertex Patents and Licensed Vertex Know-How.
1.69.    “Major [***] Countries” means the [***].
1.70.    “Manufacture”, “Manufactured” or “Manufacturing” means activities directed to making, having made, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality control testing and quality assurance release, shipping or storage of a Product (including any [***] that comprise such Product). 
1.71.    “Manufacturing Budget” has the meaning set forth in Section 6.2.
1.72.    “Manufacturing Costs” means [***]
1.73.    “[***]” has the meaning set forth in Section 6.1.
1.74.    “Manufacturing Working Group” has the meaning set forth in Section 6.2.
1.75.    “Medical Affairs Activities” means responding to external inquiries or complaints, the planning for and conduct of investigator sponsored Clinical Trials not included in the Global Development Plan, medical education, speaker programs, advisory boards, thought leader activities, educational grants and fellowships, local country government affairs, phase 3b Clinical Trials, phase IV/post-Regulatory Approval Clinical Trials, generating health economics and outcomes research data from patient reported outcomes, prospective observational studies and retrospective observational studies, and economic models and reimbursement dossiers, deployment of MSLs, medical affairs clinical trial management, doctors in field (other than MSLs), scientific publications and medical communications.
1.76.    “Medical Affairs Budget” has the meaning set forth in ARTICLE 4.
1.77.    “Medical Affairs Costs” means all Expenses incurred by the Parties in connection with the conduct of Medical Affairs Activities in accordance with the Medical Affairs Plan and the Medical Affairs Budget.
1.78.    “Medical Affairs Plan” has the meaning set forth in ARTICLE 4.
1.79.    “MSL” means medical science liaisons.
1.80.    “Net Loss” means, for a given period, Net Sales in the Territory plus Sublicense Revenue less Program Expenses, where the result is a negative number.
1.81.    “Net Profit” means, for a given period, Net Sales in the Territory plus Sublicense Revenue less Program Expenses, where the result is a positive number.
7

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.82.    “Net Sales” means the gross invoiced price for Shared Products sold by a Party or its Affiliates (the “Selling Party”) to Third Parties, less the following deductions from such gross amounts: 
(a)    [***]; 
(b)    [***]; 
(c)    [***]; 
(d)    [***];
(e)    [***].
Generally, only items that are deducted from the Selling Party’s gross invoiced sales price of Shared Product(s), as included in the Selling Party’s published financial statements and that are in accordance with GAAP, applied on a consistent basis, will be deducted from such gross invoiced sales price for purposes of the calculation of Net Sales. However, compulsory payments required by federal or state governments based upon sales volume or market share of Shared Products (but for clarity excluding taxes on the Selling Party’s net income), to the extent borne by the Selling Party, will be deducted from “Net Sales” regardless of its classification in the Selling Party’s published financial statements; provided that any such deduction will be limited to that share of such compulsory payment proportional to the share of the total sales volume or market share of the Selling Party used to compute the compulsory payment represented by applicable Net Sales of Shared Products.
A qualifying amount may be deducted only once regardless of the number of the preceding categories that describe such amount. If a Selling Party makes any adjustment to such deductions after the associated Net Sales have been reported pursuant to this Agreement, the adjustments will be reported with the next Summary Statement. Sales between or among a Party, its Affiliates and Sublicensees will be excluded from the computation of Net Sales if such sales are not intended for end use, but Net Sales will include the subsequent final sales to Third Parties by a Party or any such Affiliates or Sublicensees.  A Shared Product will not be deemed to be sold if the Shared Product is provided free of charge to a Third Party in reasonable quantities as a sample consistent with industry standard promotional and sample practices. [***].
If a sale, transfer or other disposition with respect to Shared Products involves consideration other than cash or is not at arm’s length, then the Net Sales from such sale, transfer or other disposition will be calculated on the [***].
Solely for purposes of calculating Net Sales, if a Party or its Affiliates or any permitted Sublicensee sells a Shared Product in the form of a combination product 
8

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

containing a Shared Product and one or more other therapeutically or prophylactically active ingredients or delivery devices (whether combined in a single formulation or package, as applicable, or formulated separately but packaged under a single label approved by a Regulatory Authority and sold together for a single price) (a “Combination Product”), Net Sales of such Combination Product will be calculated by multiplying actual Net Sales of such Combination Product as determined in the first paragraph of the definition of “Net Sales” by the fraction A/(A+B) where [***]. The weighted average invoice prices referenced above will be calculated with reference to the prevailing prices during the applicable Calendar Quarter in those top selling countries that equate to [***]% of Net Sales of the applicable Shared Product in the Territory, with the prices weighted in the calculation to reflect the actual relative sales value of the Shared Product in each of the countries to which the calculation relates. If it is not possible to determine the fraction A/(A+B) based on the criteria specified in the preceding sentence (e.g., if a Shared Product component is not sold separately), the Parties shall determine Net Sales for the Shared Product in such Combination Product in good faith by mutual agreement [***].
1.83.    “Non-Challenging Party” has the meaning set forth in Section 14.2.3.
1.84.    “Opt-Out” has the meaning set forth in Section 14.3.1.
1.85.    “Opt-Out Product” has the meaning set forth in Section 14.3.1.
1.86.    “Opt-Out Royalties” has the meaning set forth in Section 14.3.1.
1.87.    “Other Out-of-Pocket Costs” means:
1.87.1.    [***];
1.87.2.    [***];
1.87.3.    [***];
1.87.4.    [***].
1.88.    “Party” or “Parties” has the meaning set forth in the Preamble.
1.89.    “Patent Challenge” has the meaning set forth in Section 14.2.3.
1.90.    “Patent Costs” means all Expenses reasonably allocated to the Shared Products for the prosecution, maintenance and enforcement of Patents that Cover the Shared Products.
1.91.    “Pharmacovigilance Agreement” has the meaning set forth in Section 8.1.
1.92.    “Physician Lead” has the meaning set forth in Section 3.2.2.
9

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

1.93.    “Product” means a Shared Product or a Follow-On Product.
1.94.    “[***] Claim” means a claim in any Patent that [***].
1.95.    “Program Expenses” [***]. 
1.96.    “Project Team” has the meaning set forth in Section 3.2.1.
1.97.    “Quality Agreement” has the meaning set forth in Section 3.3.6.
1.98.    “Quality Costs” mean all Expenses incurred by the Parties and their respective Affiliates in conducting the activities set forth in the Quality Agreement.
1.99.    “Reconciliation Report” has the meaning set forth in Section 7.6.
1.100.    “Regional Commercialization Plan” has the meaning set forth in Section 5.2.
1.101.    “Research Budget” has the meaning set forth in Section 3.1.2.
1.102.    “Research Costs” [***]. 
1.103.    “[***]” has the meaning set forth in Section 6.1.
1.104.    “[***]” has the meaning set forth in Section 6.1.
1.105.    “[***]” has the meaning set forth in Section 12.6.
1.106.    “Selling Party” has the meaning set forth in Section 1.82. 
1.107.    “Shared Product” means (a) the Initial Shared Product and (b) if any Follow-On Product is deemed to be a Shared Product pursuant to Section 3.5, such Follow-On Product. 
1.108.    “Shared Target” means (a) [***], (b) [***], (c) the [***], (d) [***] and (e) [***] [***] Target added as a Collaboration Target under the Collaboration Agreement. 
1.109.    “Specified Regulatory Activities” [***].
1.110.    “Subcontract” has the meaning set forth in ARTICLE 9.
1.111.    “Subcontractor” has the meaning set forth in ARTICLE 9.
1.112.    “Sublicense Revenue” [***].
1.113.    “Sublicensee” means an Affiliate or Third Party, other than a Distributor, to whom either Party (or a Sublicensee or Affiliate) licenses or sublicenses such Party’s rights under the Licensed CRISPR Technology or the Licensed Vertex 
10

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Technology, in each case, with respect to a Shared Product during the Co-Co Agreement Term. 
1.114.    “Summary Statement” has the meaning set forth in Section 7.5.
1.115.    “Terminated Product” has the meaning set forth in Section 14.4.
1.116.    “Third Party Obligations” means any non-financial encumbrances, obligations, restrictions, or limitations imposed by a [***] that are required to be passed through to a sublicensee of the [***], as applicable, and relate to a Product or a Shared Target, including field or territory restrictions, covenants, diligence obligations or limitations pertaining to enforcement of intellectual property rights.
1.117.    “Trademark” means all trademarks, service marks, trade names, brand names, sub-brand names, trade dress rights, product configuration rights, certification marks, collective marks, logos, taglines, slogans, designs or business symbols and all words, names, symbols, colors, shapes, designations or any combination thereof that function as an identifier of source or origin or quality, whether or not registered, and all statutory and common law rights therein, and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.
1.118.    “Vertex” has the meaning set forth in the Preamble.
1.119.    “Vertex In-License Agreements” means Vertex’s or its Affiliates’ agreements with Third Party licensors or sellers listed on Schedule F, which Schedule shall be updated upon the designation of any Follow-On Product as a Shared Product under this Agreement, to include any agreements pursuant to which Vertex or its Affiliates have in-licensed or acquired any Licensed Vertex Technology with respect to such Shared Product.
1.120.    “Vertex Parent” has the meaning set forth in the Preamble.
1.121.    “Vertex UK” has the meaning set forth in the Preamble.
ARTICLE 2
GOVERNANCE

2.1.    Joint Steering Committee.
2.1.1.    Formation. Within [***] Business Days after the Effective Date, the Parties will establish a joint steering committee (the “JSC”) to provide high-level oversight and decision-making regarding the activities of the Parties under this Agreement. The JSC will be comprised of [***] representatives from each Party, or such other number of equal representatives as the Parties may mutually agree upon. The JSC will 
11

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

conduct its responsibilities hereunder in good faith and with reasonable care and diligence. The JSC will meet at least once each Calendar Quarter, or as otherwise mutually agreed by the Parties in writing, on such dates and at such times and places as agreed to by the members of the JSC, and will use good faith efforts to conduct any such meeting in person. The purpose of the JSC will be to provide the members periodic updates regarding progress of activities pursuant to this Agreement and to address the matters set forth in Section 2.1.2. Each Party will be responsible for its own expenses relating to attendance at or participation in JSC meetings.
2.1.2.    Responsibilities. The JSC will:
(a)    review and oversee the overall global Development, Manufacture and Commercialization of the Shared Products and the Research of the Follow-On Products in the Field;
(b)    oversee the JDC, JCC, JMC, Patent Coordinators, the Parties’ commercial representatives prior to the establishment of the JCC, and any other committees and working groups established with respect to the Products and resolving matters on which the JDC, JCC, JMC, Patent Coordinators, commercial representatives or such committees and working groups are unable to reach consensus;
(c)    review and discuss any amendments or updates to the Global Development Plan submitted by the JDC;
(d)    review and discuss the initial Follow-On Research Plan, and any amendments or updates thereto, submitted by the JRC;
(e)    review and discuss any amendments or updates to the Global Manufacturing Plan submitted by the JMC;
(f)    review and discuss the initial Global Commercialization Plan for each Shared Product and any amendments or updates thereto submitted by the JCC;
(g)    upon recommendation by the JRC, and in consultation with the JDC, determine whether each Follow-On Product will be designated as a Shared Product under this Agreement; 
(h)    review and attempt to resolve any disputes regarding [***]; 
(i)    compile, discuss and approve the Integrated Budget no later than [***] of each Calendar Year; and
12

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(j)    perform such other duties as are specifically assigned to the JSC under this Agreement.
2.2.    Joint Research Committee.
2.2.1.    Generally. The JRC established under the Collaboration Agreement will, in addition to its obligations under the Collaboration Agreement, provide oversight and decision-making regarding the Research activities of the Parties with respect to Follow-On Products under this Agreement. The provisions of Section 3.1.1 of the Collaboration Agreement will apply with respect to meetings of the JRC.  For clarity, any decisions to be made by the JRC under this Agreement will be subject to Section 2.8 of this Agreement, and not Section 3.1.3 of the Collaboration Agreement.
2.2.2.    Responsibilities. The JRC will:
(a)    oversee the Research of the Follow-On Products by the Parties in the Field in the Territory;
(b)    prepare, discuss and approve, in consultation with the JDC, the initial Follow-On Research Plan (including the Research Budget) and any amendments or updates thereto, and submit such initial Follow-On Research Plan and such amendments or updates to the JSC for review and discussion;
(c)    submit the approved updated Research Budget for the subsequent Calendar Year to the JSC for inclusion in the Integrated Budget no later than [***] of each Calendar Year; 
(d)    review and attempt to resolve any disputes regarding the protocol for any non-clinical study conducted under the Global Development Plan or the Follow-On Research Plan; 
(e)    submit recommendations to the JSC regarding the advisability of designating a Follow-On Product as a Shared Product under this Agreement; 
(f)    review, discuss and approve any proposed use of a Subcontractor to conduct a Party’s activities under the Follow-On Research Plan, where the applicable Subcontract is anticipated to entail payments in excess of $[***], as set forth in ARTICLE 9; and
(g)    perform such other duties as are specifically assigned to the JRC under this Agreement or as may be delegated to the JRC by the JSC.
13

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

2.2.3.    Discontinuation of the JRC. Notwithstanding anything to the contrary in the Collaboration Agreement, the JRC will disband with respect to this Agreement upon mutual agreement of the Parties following the completion of all substantive Research activities with respect to the Follow-On Products under this Agreement, but shall be reestablished if either or both Parties desires to engage in additional Research activities with respect to any Follow-On Product. 
2.3.    Joint Development Committee.
2.3.1.    Formation. Within [***] Business Days after the Effective Date, the Parties will establish a joint development committee (the “JDC”) to provide oversight and decision-making regarding the Development activities of the Parties under this Agreement. The JDC will be comprised of [***] representatives from each Party, or such other number of equal representatives as the Parties may mutually agree upon. The JDC will conduct its responsibilities hereunder in good faith and with reasonable care and diligence. The JDC will meet at least once each Calendar Quarter, or as otherwise mutually agreed by the Parties, on such dates and at such times and places as agreed to by the members of the JDC, and will use good faith efforts to conduct any such meeting in person. The purpose of the JDC will be to facilitate and provide the members periodic updates regarding progress of Development activities pursuant to this Agreement and to address the matters set forth in Section 2.3.2. Each Party will be responsible for its own expenses relating to attendance at or participation in JDC meetings.
2.3.2.    Responsibilities. The JDC will:
(a)    oversee the Development of the Shared Products and the Research strategy for the Follow-On Products by the Parties in the Field in the Territory;
(b)    review, discuss and approve the initial Global Development Plan (including the Development Budget) and any updates or amendments thereto proposed by the Project Team, and submit such Global Development Plan, updates or amendments to the JSC for review and discussion;
(c)    submit the approved updated Development Budget for the subsequent Calendar Year to the JSC for inclusion in the Integrated Budget no later than [***] of each Calendar Year; 
(d)    oversee the Project Team and attempt to resolve any matters on which the Project Team is unable to reach consensus; 
14

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(e)    review, discuss and approve clinical and regulatory strategic options for the Shared Products as proposed by the Project Team;
(f)    review, discuss and approve the first IND for the Initial Shared Product to be submitted to the applicable Regulatory Authorities in accordance with Section 3.3.1(c);
(g)    review and consult with the JRC regarding the initial Follow-On Research Plan and any updates or amendments thereto proposed by the JRC;
(h)    inform and provide guidance to the JSC regarding any quality or compliance-related risks with respect to the Development of the Products;
(i)    provide guidance to the Project Team with respect to pre-clinical and clinical quality matters for the Products; 
(j)    review, discuss and approve regulatory activities for the Shared Products proposed by the Project Team, including determining the strategy with respect to each material Regulatory Filing or material regulatory interaction with respect to the Shared Products;
(k)    allocate responsibilities for the conduct of Clinical Trials under the Global Development Plan to the Parties, which allocation will be consistent with Section 3.2 and Section 3.3.2;
(l)    review, discuss and approve changes to the Project Team membership in accordance with Section 3.2;
(m)    review and attempt to resolve any disputes regarding the protocol or statistical analysis plan for any Clinical Trial conducted under the Global Development Plan; 
(n)    provide guidance to the JSC regarding the advisability of designating a Follow-On Product as a Shared Product under this Agreement; 
(o)    develop and agree upon the Medical Affairs Plan for the Shared Products and determine the number of MSLs to be deployed in each jurisdiction in the Territory;
(p)    consult with the JMC in connection with its oversight of the Manufacturing Working Group with respect to matters relating to the pre-clinical or clinical Manufacture of the Products; 
15

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(q)    consult with the JMC in connection with its oversight of the pre-clinical and clinical Manufacture of the Products in the Field in the Territory; 
(r)    consult with the JMC in connection with its review and discussion of any updates to the Global Manufacturing Plan, including the Manufacturing Budget, proposed by the Manufacturing Working Group; 
(s)    consult with the JMC in connection with its review, discussion and approval of the Manufacturing process, and any changes thereto, for each Shared Product; 
(t)    consult with the JMC and the Manufacturing Working Group in connection with their review of Manufacturing quality matters for the Products and its oversight of Manufacturing quality matters set forth in the Quality Agreement;
(u)    consult with the JMC in connection with its review of the results of regulatory and environmental, health and safety inspections and audits related to the Manufacture of the Products and its review and discussions of steps taken by CRISPR to address any deficiencies noted;
(v)    review, discuss and approve any proposed use of a Subcontractor to conduct a Party’s activities under the Global Development Plan or the Quality Agreement, where the applicable Subcontract is anticipated to entail payments in excess of $[***], as set forth in ARTICLE 9; and
(w)    perform such other duties as are specifically assigned to the JDC under this Agreement or as may be delegated to the JDC by the JSC.
2.3.3.    Discontinuation of the JDC. The JDC will disband upon mutual agreement of the Parties following the completion of all substantive Research and Development activities under this Agreement, but shall be reestablished if either or both Parties desires to engage in additional Research or Development activities with respect to any Product. 
2.4.    Joint Commercialization Committee.
2.4.1.    Formation. Within [***] days following Establishment of POC for a Shared Product, the Parties will establish a joint commercialization committee (the “JCC”) to provide oversight and decision-making regarding the Commercialization activities of the Parties under this 
16

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Agreement, provided that, prior to establishment of the JCC, commercial representatives of the Parties will meet on an ad hoc basis, as reasonably requested by either Party, to discuss commercial matters for the Shared Products; and provided, further, that any dispute between such commercial representatives with regard to any commercial matter for a Shared Product shall be referred to the JSC for resolution. The JCC will be comprised of [***] representatives from each Party, or such other number of equal representatives as the Parties may mutually agree upon. The JCC will conduct its responsibilities hereunder in good faith and with reasonable care and diligence. The JCC will meet at least once each Calendar Quarter, or as otherwise mutually agreed by the Parties, on such dates and at such times and places as agreed to by the members of the JCC, and will use good faith efforts to conduct any such meeting in person. The purpose of the JCC will be to facilitate and provide the members periodic updates regarding progress of Commercialization activities pursuant to this Agreement and to address the matters set forth in Section 2.4.2. Each Party will be responsible for its own expenses relating to attendance at or participation in JCC meetings.
2.4.2.    Responsibilities. The JCC will:
(a)    oversee the Commercialization of the Shared Products by the Parties in the Field in the Territory;
(b)    develop and approve a Global Commercialization Plan for each Shared Product and submit such Global Commercialization Plan to the JSC for review and discussion;
(c)    amend the Global Commercialization Plan for each Shared Product on an annual basis (or more frequently as needed), approve such amendments and submit such updated Global Commercialization Plans to the JSC for review and discussion;
(d)    review, discuss and approve the initial Regional Commercialization Plans for each Shared Product and any amendments or updates thereto submitted by Parties; 
(e)    select product Trademarks for each Shared Product throughout the world consistent with the Global Brand Strategy;
(f)    advise the JMC in connection with its oversight of the Manufacturing Working Group with respect to matters relating to the commercial Manufacture of the Shared Products; 
17

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(g)    advise the JMC in connection with its oversight of the commercial Manufacture of the Shared Products in the Field in the Territory; 
(h)    advise the JMC in connection with its review and discussion of any updates to the Global Manufacturing Plan, including the Manufacturing Budget, proposed by the Manufacturing Working Group; 
(i)    submit the approved updated Global Commercialization Budget for the subsequent Calendar Year to the JSC for inclusion in the Integrated Budget no later than [***] of each Calendar Year;
(j)    advise the JMC in connection with its review, discussion and approval of the Manufacturing process, and any changes thereto, for each Shared Product; 
(k)    review, discuss and approve any proposed use of a Subcontractor to conduct a Party’s activities under a Global Commercialization Plan, where the applicable Subcontract is anticipated to entail payments in excess of $[***], as set forth in ARTICLE 9; and
(l)    perform such other duties as are specifically assigned to the JCC under this Agreement or as may be delegated to the JCC by the JSC.
2.5.    Joint Manufacturing Committee.
2.5.1.    Formation. Within [***] Business Days after the Effective Date, the Parties will establish a joint manufacturing committee (the “JMC”) to provide oversight and decision-making regarding the Manufacture of pre-clinical, clinical and commercial supply of the Products under this Agreement. The JMC will be comprised of [***] representatives from each Party, or such other number of equal representatives as the Parties may mutually agree upon. The JMC will conduct its responsibilities hereunder in good faith and with reasonable care and diligence. The JMC will meet on a [***] basis for the first [***] after the Effective Date, or as otherwise mutually agreed by the Parties, and, thereafter, at least once each Calendar Quarter, or as otherwise mutually agreed by the Parties, on such dates and at such times and places as agreed to by the members of the JMC, and will use good faith efforts to conduct any such meeting in person. The purpose of the JMC will be to facilitate and provide the members periodic updates regarding progress of Manufacturing activities pursuant to this Agreement and to address the matters set forth in Section 2.5.2. Each Party will be responsible for its own expenses relating to attendance at or participation in JMC meetings.
18

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

2.5.2.    Responsibilities. The JMC will: 
(a)    consistent with the provisions of Section 6.2, designate the team leader and other members of the Manufacturing Working Group, which team leader and members shall be chosen from among the personnel of the Parties having relevant experience, and allocate the respective roles on the Manufacturing Working Group among such members; 
(b)    review on a periodic basis and make any necessary changes to the team leader and other members of the Manufacturing Working Group, or the allocation of roles among such members;
(c)    oversee the Manufacturing Working Group, in consultation with the JDC, with respect to matters relating to the pre-clinical or clinical Manufacture of the Products; 
(d)    oversee the Manufacturing Working Group, in consultation with the JCC, with respect to matters relating to the commercial Manufacture of the Products;
(e)    oversee the Manufacturing Working Group, in consultation with the JDC, with respect to Manufacturing quality matters for the Products;
(f)    oversee the Manufacturing Working Group, in consultation with the JDC, with respect to the review of the results of regulatory and environmental, health and safety inspections and audits related to the Manufacture of the Products and the review and discussion of steps taken by CRISPR to address any deficiencies noted; 
(g)    oversee the Manufacture of the Products in the Field in the Territory, in consultation with the JDC or JCC, as applicable;
(h)    allocate responsibilities for Manufacturing activities with respect to the Products in the Field in the Territory between the Parties;
(i)    review, discuss and approve, in consultation with the JDC or the JCC, as applicable, the initial Global Manufacturing Plan, including the Manufacturing Budget, and any updates or amendments thereto proposed by the Manufacturing Working Group, and submit such Global Manufacturing Plan, updates or amendments to the JSC for review and discussion;
19

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(j)    submit the approved updated Manufacturing Budget for the subsequent Calendar Year to the JSC for inclusion in the Integrated Budget no later than [***] of each Calendar Year;
(k)    review, discuss and approve the Manufacturing process for each Shared Product proposed by the Manufacturing Working Group, and review, discuss and approve any changes to such Manufacturing process proposed by the Manufacturing Working Group, in each case, in consultation with the JDC or JCC, as applicable;
(l)    review, discuss and approve any recommendations of the Manufacturing Working Group regarding capacity planning, supply plans and supply continuity planning for the Products;
(m)    select and approve each CMO and contract testing facility to be engaged with respect to each phase of the Manufacture of any Product [***]; 
(n)    determine whether any Manufacturing technology transfer between the Parties is necessary; 
(o)    review, discuss and approve any proposed use of a Subcontractor to conduct a Party’s activities under the Global Manufacturing Plan, where the applicable Subcontract is anticipated to entail payments in excess of $[***], as set forth in ARTICLE 9; and
(p)    perform such other duties as are specifically assigned to the JMC under this Agreement or as may be delegated to the JMC by the JSC.
2.6.    Alliance Managers. 
2.6.1.    Appointment.  Each Party will appoint a representative of such Party to act as its alliance manager under this Agreement (each, an “Alliance Manager”). Each Party may replace its Alliance Manager at any time by written notice to the other Party. 
2.6.2.    Specific Responsibilities.  The Alliance Managers will serve as the primary contact point between the Parties for the purpose of providing each Party with information regarding the other Party’s activities pursuant to this Agreement and will have the following responsibilities:
(a)    schedule meetings of the JSC, JDC, JCC, and JMC and circulate draft written minutes from each meeting within 14 days after 
20

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

each such meeting to the applicable committee, all other committees and the Project Team; 
(b)    facilitate the flow of information and otherwise promote communication, coordination and collaboration between the Parties;
(c)    coordinate the various functional representatives of each Party, as appropriate, in developing and executing strategies and plans for the Products;
(d)    provide a single point of communication for seeking consensus both internally within the respective Party's organization and between the Parties regarding key strategy and planning issues;
(e)    coordinate and facilitate budget, finance and billing activities as overseen by the JSC, JDC, JCC, and JMC; and
(f)    perform such other functions as requested by the JSC, JDC, JCC, or JMC. 
2.7.    Other Committees.  The Parties may, by mutual agreement, form such other committees or working groups as may be necessary or desirable to facilitate the activities under this Agreement. 
2.8.    Decision-Making.  The JSC, JDC, JCC, JMC, JRC and all other committees and working groups will operate by consensus with the goal being to leverage capabilities, minimize cost and maximize the chance of successfully Developing and Commercializing each Shared Product throughout the Territory in a commercially reasonable manner consistent with Applicable Laws and this Agreement. Disputes arising out of the JDC, JCC, JMC, JRC or any other committee or working group will be escalated to the JSC for resolution. Disputes arising at the JSC will be referred to the Executive Officers for resolution, whereupon the Executive Officers will meet in person if requested by either such Executive Officer and attempt in good faith to resolve such dispute by negotiation and consultation for a [***]-day period following such referral. If the Executive Officers do not resolve such dispute within such [***]-day period, such dispute shall be [***].  Notwithstanding anything to the contrary, none of the JSC, JDC, JCC, JMC, JRC or any other committee or working group will have the authority to amend or waive compliance with any of the terms of this Agreement. For clarity, with respect to the Global Development Plan, the Medical Affairs Plan, Global Manufacturing Plan or any Global Commercialization Plan or Regional Commercialization Plan, each Party shall have decision-making authority regarding its implementation of such Global Development Plan, Medical Affairs Plan, Global Manufacturing Plan, Global Commercialization Plan or Regional Commercialization Plan in its respective territory, in such Party’s sole discretion, 
21

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

provided that such implementation is consistent with the then-approved applicable plan and budget, and any such implementation decision shall not be subject to dispute resolution by any committee or working group, escalation to the Executive Officers [***] pursuant to this Section 2.8.
ARTICLE 3
DEVELOPMENT

3.1.    Research and Development Plans. 
3.1.1.    Global Development Plan.  The JDC will oversee the Development of the Shared Products and the Research of Follow-On Products by the Parties in the Field in the Territory. The Shared Products will be Developed in accordance with a global development plan (the “Global Development Plan”), which will include the Development Budget (as defined below), which will be prepared by the Project Team within [***] days after the Effective Date and shall be approved by the JDC thereafter. Unless otherwise agreed by the Parties in writing, the Global Development Plan will at all times include a plan for the Development of the Shared Products in the Territory through Regulatory Approval, including a regulatory strategy, high-level study design criteria, an allocation of responsibilities between the Parties, timelines and a budget for activities conducted under the Global Development Plan (the “Development Budget”).  Until such time as the initial Development Budget has been established in accordance with this Agreement, each Party will incur Program Expenses in a manner substantially consistent with the plans and budgets previously discussed by the Parties and such Program Expenses will be shared as provided in ARTICLE 7. On [***] basis (or more frequently as needed), the Project Team will update the Global Development Plan and will submit the updated Global Development Plan to the JDC for review and discussion. The JDC will review and discuss the updated Global Development Plan and submit such updated Global Development Plan to the JSC for review, discussion and approval.
3.1.2.    Follow-On Research Plan.  The Parties will conduct Research activities with respect to the Follow-On Products in accordance with a Follow-On research plan (the “Follow-On Research Plan”), including a budget for activities conducted under the Follow-On Research Plan (the “Research Budget”), the initial version of which will be prepared by the JRC in consultation with the JDC promptly following the Effective Date and submitted to the JSC for review, discussion and approval. In addition[***] basis (or more frequently as needed), the JRC in consultation with the JDC will update the Follow-On Research Plan and 
22

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

will submit the updated Follow-On Research Plan to the JSC for review, discussion and approval. For clarity, all Research Costs with respect to the Follow-On Products shall be treated under this Agreement as part of Program Expenses, and not under Section 2.10 or Section 7.4 of the Collaboration Agreement. 
3.2.    Project Team. 
3.2.1.    Formation; Responsibilities. The Parties will establish a project team (the “Project Team”) to oversee and coordinate activities under the Global Development Plan. The Project Team will include members from each function identified on Schedule C-1. The initial Project Team members are set forth on Schedule C-2. If a Project Team member is no longer available to serve on the Project Team, the Parties will meet and discuss an appropriate replacement for such Project Team member from either Party, taking into account each Party’s expertise and resources in the relevant functional area. The appointment of the replacement Project Team member will require the JDC’s approval. Any member of the Project Team who is not dedicated to the Products under this Agreement on a full-time basis must be sufficiently dedicated to such Products to permit such person to be reasonably and consistently available to participate in the activities of the Project Team. The Project Team will be responsible for: (i) defining clinical and regulatory strategic options for recommendation to the JDC; (ii) providing guidance on regulatory activities for recommendation to the JDC; (iii) preparing joint deliverables, including updates to the Global Development Plan for submission to the JDC; (iv) preparing study protocols and statistical analysis plans for approval in accordance with Section 3.3.2(b); (v) preparing regulatory documentation for recommendation to the JDC; (vi) proposing goals, budgets and timelines for joint Development activities to the JDC; (vii) driving execution and ensuring the progress of Development activities in accordance with the Global Development Plan; and (viii) such additional matters as may be determined by the JDC. The Project Team shall act by consensus, with each Party’s representatives on the Project Team having collectively one vote.  If the Project Team cannot reach consensus, the matter will be referred to the JDC for resolution. 
3.2.2.    Physician Leads and Clinical Operations Study Leads. Each Party will be responsible for designating its own physician leads (each, a “Physician Lead”) and clinical operations study leads (each, a “Clinical Operations Study Lead”), subject to the approval of the JDC. [***] will initially appoint the Physician Lead for each Initial Clinical Trial; provided that (i) with respect to the Initial Clinical Trial for sickle cell disease, the Physician Lead appointed by [***] shall be responsible for 
23

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

such Initial Clinical [***], and (ii) the Physician Leads for each Initial Clinical Trial will at all times cooperate to share information and oversee both Initial Clinical Trials in a collaborative manner. [***] will appoint the Clinical Operations Study Lead for the Initial Clinical Trial for beta-thalassemia and [***] will appoint the Clinical Operations Study Lead for the Initial Clinical Trial for sickle cell disease. With respect to each Clinical Trial other than an Initial Clinical Trial, the JDC will determine the roles and responsibilities of the Parties’ respective Physician Leads and Clinical Operations Study Leads.
3.2.3.    Clinical Pharmacology. [***] will be responsible for all clinical pharmacology matters with respect to the Shared Products, as further detailed in the Global Development Plan.  
3.2.4.    Biostatistics. [***] will initially be responsible for biostatistics matters with respect to the Shared Products including the performance of the biostatistics activities set forth in the Global Development Plan in accordance with the Global Development Plan. [***] upon [***], as determined by the JDC [***].
3.2.5.    Conduct; Reporting. The Project Team will conduct its responsibilities under the Global Development Plan in good faith and with reasonable care and diligence. The Project Team will provide the JDC with periodic updates (but no less than quarterly) regarding the progress of activities pursuant to the Global Development Plan. 
3.3.    Development Activities.
3.3.1.    Regulatory Matters. 
(a)    Regulatory activities will be jointly carried out by the Parties and the Project Team under the guidance of the JDC in accordance with this Section 3.3.1. The Party responsible for regulatory activities under this Section 3.3.1 will be responsible for keeping the Project Team apprised as to the status of such activities and consulting with the Project Team as provided herein and the Project Team will be responsible for keeping the JDC apprised as to the status of such activities and consulting with the JDC as provided herein. All regulatory activities will be conducted using [***] standard regulatory operating procedures and systems. 
(b)    All Regulatory Filings and Regulatory Approvals that relate to the Shared Products shall be filed by and held in the name of [***] or its designated Affiliates, except that: (i) [***] shall initially hold the [***] CTAs submitted for the first Shared Product for beta-thalassemia to Regulatory Authorities in the 
24

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

[***] in the name of [***] or its designated Affiliates, and, unless the JDC otherwise determines that the transfer of such CTAs to [***] as provided herein [***], shall initiate transfer of such CTAs to [***] within [***] days after approval or rejection of such CTAs in any [***], and thereafter, unless otherwise agreed by the Parties in writing, such CTAs, and any subsequent CTA for a Shared Product, shall be held in the name of [***] or its designated Affiliate and [***] shall be the sponsor for the Initial Clinical Trials; (ii) [***] shall initially hold the first IND submitted for the first Shared Product to the FDA in the name of [***] or its designated Affiliates, and, unless the JDC otherwise determines that the transfer of such IND to [***] as provided herein [***], shall initiate transfer of such IND to [***] no later than [***] after such IND becomes effective or the FDA places a hold on such IND (the “IND Transfer Date”), and thereafter, unless otherwise agreed by the Parties in writing, such IND, and any subsequent IND for a Shared Product, shall be held in the name of [***] or its designated Affiliate; and (iii) [***] or its designated Affiliate, and thereafter [***] or its designated Affiliate. Each Party agrees to take such further actions as may be reasonably necessary to effect the transfers set forth in this Section 3.3.1(b). The Project Team will oversee, monitor and manage the transfers contemplated by this Section 3.3.1(b). A transfer initiated under this Section 3.3.1(b) will proceed without undue delay and shall not be halted, delayed or paused after it has been so initiated and each Party will use Commercially Reasonable Efforts to effectuate such transfer as soon as possible. Prior to the transfer of any Regulatory Filing to [***] under this Section 3.3.1(b), [***] will provide [***] with copies of all source documents related to such first three CTAs or such IND, and any updates thereto.
(c)    The Parties acknowledge that, prior to the Effective Date, [***] submitted the [***] for the Initial Shared Product for beta-thalassemia to Regulatory Authorities in [***] in the name of [***] or its designated Affiliate, and the Parties acknowledge and agree that, after the Effective Date, [***] will submit a [***] for the Initial Shared Product for beta-thalassemia in [***] in the name of [***] or its designated Affiliate, in substantially the same form as the [***] such CTAs. With respect to the first IND for the Initial Shared Product to be submitted by [***] after the Effective Date as provided in Section 3.3.1(b), [***], in consultation with the Project Team and in accordance with the strategy approved by the JDC, will prepare such IND, and provide [***] with advance drafts of such IND, and any related 
25

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

regulatory submissions or correspondence, that [***] plans to submit to the applicable Regulatory Authority as drafts are prepared and in all cases sufficiently in advance so as to afford [***] a meaningful opportunity to review such IND. [***] may provide comments regarding such IND, and related regulatory submissions or correspondence, prior to their submission, and [***] will incorporate any such comments. [***] will file such IND, and submit such related regulatory submissions or correspondence, only in the final form approved by the JDC. Thereafter, until such time that such CTAs and such IND are transferred to [***], [***] will oversee, monitor and manage all regulatory interactions and communications with Regulatory Authorities. [***] may provide comments regarding such interactions and correspondence, and [***] will incorporate any such comments. [***] will also provide [***] with final copies of all material submissions it makes to, and all material correspondence it receives from, a Regulatory Authority pertaining to such CTAs and such IND for the Initial Shared Product, within [***] Business Days after such submission or receipt. After [***] transfers such CTAs and IND to [***], [***] shall be responsible for all communications and correspondence with applicable Regulatory Authorities, consistent with Section 3.3.1(d). 
(d)    Following transfer of the [***] CTAs in beta-thalassemia and the first IND for the Initial Shared Product to [***], [***] shall use Commercially Reasonable Efforts, in consultation with [***], to seek to obtain Regulatory Approvals for the Shared Products in the Field and to maintain such Regulatory Approvals outside of the [***]. [***], [***] shall use Commercially Reasonable Efforts, in consultation with [***], to [***]. Subject to the terms of this Agreement, [***], in consultation with the Project Team and in accordance with the strategy approved by the JDC, will lead all regulatory activities, including all regulatory interactions and communications and determining the labeling strategy for the Shared Product, and will prepare and submit all Regulatory Filings with respect to the Shared Products to the appropriate Regulatory Authorities in the Territory, provided that [***] may review and comment on such strategies and submissions, which comments [***] will consider in good faith (and the Parties will discuss any material comments that are not incorporated or otherwise reflected in any of the foregoing), provided, further, that [***], in consultation with the Project Team and in accordance with the strategy approved by the JDC, will oversee, monitor and manage any such regulatory interactions, 
26

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

communications and filings [***]. [***] will provide [***]with advance drafts of any material documents or other material correspondence pertaining to the Shared Products that [***] plans to submit to any Regulatory Authority as drafts are prepared and in all cases sufficiently in advance so as to afford [***] a meaningful opportunity to review such drafts. [***] may provide comments regarding such documents and other correspondence prior to their submission, which comments [***] will consider in good faith (and the Parties will discuss any material comments that are not incorporated or otherwise reflected in any of the foregoing); provided that, notwithstanding anything to the contrary set forth in this Agreement, with respect to any Specified Regulatory Activities to be performed by or on behalf of [***], unless otherwise required by Applicable Law [***] will not perform, and will prevent others from performing, any Specified Regulatory Activities [***].  Notwithstanding the foregoing, [***], in consultation with the Project Team and in accordance with the strategy approved by the JDC, will control all regulatory activities with respect [***] for each Shared Product [***] in accordance with the strategy approved by the JDC. [***] will provide [***] with advance drafts of any material documents or other material correspondence pertaining to the Shared Products that [***] plans to submit to any Regulatory Authority with respect [***] as drafts are prepared and in all cases sufficiently in advance so as to afford [***] a meaningful opportunity to review such drafts.  [***] may provide comments regarding such documents and other correspondence prior to their submission, which comments [***] will consider in good faith (and the Parties will discuss any material comments that are not incorporated or otherwise reflected in any of the foregoing); provided that, notwithstanding anything to the contrary set forth in this Agreement, with respect to any Specified Regulatory Activities to be performed by or on behalf of [***], unless otherwise required by Applicable Law [***], [***] will not perform, and will prevent others from performing, any Specified Regulatory Activities [***].  Each Party will provide the other Party with copies of all material submissions it makes to, and material correspondence it receives from, a Regulatory Authority pertaining to a Regulatory Approval of the Shared Products within [***] Business Days after such submission or receipt. To the extent practicable, each Party will provide the other Party with reasonable advance notice of any meeting or teleconference with any Regulatory Authority with respect to the Shared Products. Subject to Applicable Law, the other Party will have the right to send [***] plus up to [***] additional representatives 
27

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

of such Party to participate as observers in all material meetings, conferences and discussions by the responsible Party with Regulatory Authorities pertaining to Development of the Shared Products or Regulatory Approval of the Shared Products.  Each Party shall promptly respond (and in no event later than [***] Business Days) to any request from the other Party for additional information arising from, relating to or otherwise in connection with any of the regulatory matters described or contemplated in this Section 3.3.1.
3.3.2.    Clinical Trials. 
(a)    The JDC will allocate responsibility between the Parties for the conduct of Clinical Trials and the various other Development activities addressed in the Global Development Plan, which allocation will be consistent with this Section 3.3.2 and Section 3.2. From and after the effective time of the transfer of the [***] Agreement to [***] contemplated by Section 3.3.2(h), all Clinical Trials will be conducted using [***] standard Clinical Trial operating procedures and systems.
(b)    The Parties will cooperate to develop the protocol and statistical analysis plan for each Clinical Trial under the Global Development Plan and submit each such protocol and statistical analysis plan for review and approval by [***] internal joint protocol peer review committee, and a representative of [***] shall serve as co-chair of any such committee (or any sub-committee thereof) and shall have the right to fully participate in any such review and approval process and such co-chair shall have the right to invite a reasonable number of [***] representatives to participate in the activities of any such committee. Each protocol and statistical analysis plan will be deemed to be final following approval by [***] internal joint protocol peer review committee (as so described) with [***] consent. In the event of any dispute regarding any such protocol or statistical analysis plan, the Parties may submit such dispute to the JDC for resolution. [***].
(c)    The Party whose representative is the Clinical Operations Study Lead for a Clinical Trial will have the responsibility for directing the packaging and labeling of clinical drug supplies for such Clinical Trial, unless otherwise agreed by the Parties in writing. In furtherance of the forgoing, the Clinical Operations Study Lead will coordinate with the Clinical Operations Program Lead and the Project Team when directing such labeling.
28

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(d)    The Parties will determine by mutual agreement how to implement and carry out the day-to-day operations with respect to Clinical Trials, including staffing, timelines, number and location of Clinical Trial sites, provided that such determinations shall at all times be consistent with the Global Development Plan (including the Development Budget) and this Agreement. The Clinical Operations Program Lead will oversee, manage and direct the day-to-day operations of the applicable Clinical Trial(s), consistent with the applicable Global Development Plan (including the Development Budget) and this Agreement. Without limiting the generality of the foregoing, the Clinical Operations Program Lead can direct employees, consultants and service providers of either Party and its Affiliates to perform day-to-day Clinical Trial activities consistent with the applicable Global Development Plan (including the Development Budget) and in accordance with approved processes, GCP and ICH requirements. In furtherance of the foregoing, each Party will support the authority of the Clinical Operations Program Lead by cause its employees, consultants and service providers to cooperate with the Clinical Operations Program Lead and act consistently with the Clinical Operations Program Lead’s directions with respect to day-to-day Clinical Trial activities.
(e)    With respect to each Initial Clinical Trial, and any subsequent Clinical Trial for which a Party engages a CRO, the other Party will have the right to review and approve all clinical trial agreement templates, confidential disclosure agreement templates and any other site-facing templates used by the applicable CRO in contracting with clinical trial sites, and any modifications or updates thereto, as well as any revisions thereto proposed by the applicable clinical trial sites. The Party engaging a CRO shall ensure that such CRO uses only clinical trial agreement templates, confidential disclosure agreement templates and other site-facing templates that have been reviewed and approved by the other Party in their final form. Any such clinical trial agreement template, confidentiality agreement template or other site-facing template shall provide that such clinical trial agreement is fully assignable to the other Party or its Affiliate without consent of the clinical trial site. In addition, prior to the commencement of each Initial Clinical Trial, each Party will obtain and provide to the other Party for review a copy of each clinical trial site’s insurance policy with respect to such Initial Clinical Trial. Notwithstanding anything to the contrary, each Party will provide to the other Party with all standard operating procedures, audit results and other information received by such 
29

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Party under any CRO agreement, to the extent related to the Shared Products.
(f)    [***] will be solely responsible for management of all Clinical Trial data with respect to the Shared Products, provided that [***] shall provide [***] and its designees with access to all Clinical Trial data as follows: (i) upon [***] reasonable request, provide [***] with [***] from [***] operational clinical database within [***] Business Day of generation of such reports (but in no event later than [***] Business Days after the date of [***] request); (ii) [***], in each case, [***] by [***] clinical management; (iii) [***]; (iv) access [***]; (v) an electronic copy of [***]; and (vi) [***] will provide [***], upon [***] reasonable request, [***] will provide [***] with [***] from [***] within [***] Business Day of [***] (but in no event later than [***] Business Days after the date of [***] request).
(g)    The sponsor for each Clinical Trial under the Global Development Plan will be responsible for ensuring compliance with all Applicable Law.
(h)    Promptly following the [***] under the first CTA and IND for the Initial Shared Products, [***] shall transfer and assign to [***] the [***] Agreement. Following such transfer, [***] may elect, subject to the terms hereof, to terminate the [***] Agreement and utilize [***] for the Initial Clinical Trial for beta-thalassemia unless the JDC determines that [***] then-existing internal clinical operations staff (or, if applicable, the clinical operations staff of [***] or the [***] Agreement would [***] will determine in its sole discretion whether the Initial Clinical Trial for sickle cell[***]disease will be conducted under the [***] Agreement or [***].
(i)    Each Party shall promptly respond (and in no event later than [***] Business Days) to any request from the other Party for additional information arising from, relating to or otherwise in connection with any of the clinical trial matters (including Clinical Trial data) described or contemplated in this Section 3.3.2.
3.3.3.    Non-Clinical Studies. [***] will be responsible for conducting all non-clinical studies and other Research with respect to the Products, in accordance with the Global Development Plan and the Follow-On Research Plan, as applicable, subject to the oversight of the JDC in accordance with Section 2.3.2(a). The Parties will cooperate to develop the protocol for each non-clinical study under the Global Development 
30

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Plan or the Follow-On Research Plan, as applicable, and submit each such protocol for review and approval pursuant to each Party’s internal review process. Each protocol will be deemed to be final following approval under each Party’s internal review process. The Parties shall coordinate to ensure that the same version of each protocol is approved by both Parties. In the event of any dispute regarding any such protocol, the Parties may submit such dispute to the JRC for resolution. [***] shall provide to [***] any interim or final data or results from each non-clinical study of a Product promptly following [***] receipt thereof. 
3.3.4.    Independent Activities. Each Party shall have the right to propose additional Clinical Trials for inclusion in the Global Development Plan. A Party proposing an additional Clinical Trial shall provide to the other Party, through the JDC, a summary and rationale for such additional Clinical Trial. If the other Party does not agree to include such additional Clinical Trial in the Global Development Plan, (a) [***] and (b) [***]; provided that neither Party may conduct any Clinical Trial that [***]. The non-requesting Party will not have the right to use the data resulting from any Clinical Trial conducted by one Party outside of the Global Development Plan as permitted under this Section 3.3.4 in a substantive manner as the basis for obtaining new or expanded Regulatory Approval for a Shared Product in the Field or for post-marketing Regulatory Filings or commercial purposes for a Shared Product in the Field; provided that, if such Party desires to use the data resulting from such Clinical Trial in a substantive manner as the basis for obtaining new or expanded Regulatory Approval for a Shared Product in the Field or for commercial purposes for a Shared Product in the Field, such Party shall so inform the requesting Party and shall reimburse the requesting Party for [***]% of the Expenses of such Clinical Trial that would, if such Clinical Trial were included in the Global Development Plan, have constituted Development Costs. If [***] is the non-requesting Party, following such reimbursement, [***] shall have the right to use the data resulting from such Clinical Trial for such purposes. If [***] is the non-requesting party, following such reimbursement, [***] shall have the right to direct [***] to use the data resulting from such Clinical Trial for such purposes in conducting its activities in accordance with Section 3.3.1, [***], to utilize such data in post-marketing Regulatory Filings. Upon the request of the Party conducting an additional Clinical Trial as permitted under this Section 3.3.4, the Manufacturing Working Group shall use Commercially Reasonable Efforts to Manufacture or have Manufactured, at the requesting Party’s expense, clinical supplies for the additional Clinical Trial, but in any event, the Manufacturing Working Group shall not be required to supply clinical supplies for any Clinical Trial being conducted pursuant to this Section 3.3.4 [***].
31

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

3.3.5.    Briefing the JDC.  At each scheduled meeting of the JDC, each Party will provide detailed progress updates on activities conducted under the Global Development Plan and the Follow-On Research Plan, along with a summary of data associated with such activities, which updates and summaries will be provided to JDC members at least [***] days in advance of any JDC meeting. Such updates and summaries will be provided in a format mutually agreed to by the Parties.
3.3.6.    Quality Agreement. As promptly as possible, but no later than [***] days after the Effective Date and in any case prior to the transfer of the first CTA for the Initial Shared Product to [***], the Parties will negotiate in good faith and agree on a quality agreement for the Products, including quality analysis and control criteria for the Manufacture of the Products, electronic system compliance, responsibilities for managing Clinical Trials and pre-clinical studies, and joint decision-making criteria (the “Quality Agreement”). The Quality Agreement will be consistent with the relevant provisions of the Pharmacovigilance Agreement. 
3.4.    Diligence.  Each Party will use Commercially Reasonable Efforts to execute and to perform, or cause to be performed, the activities assigned to it in the Global Development Plan and the Follow-On Research Plan, and to cooperate with the other Party in carrying out the Global Development Plan and the Follow-On Research Plan in accordance with the timelines therein. Each Party and its Affiliates will conduct its Research and Development activities in good scientific manner and in compliance with Applicable Law. Notwithstanding anything to the contrary contained herein, a Party or its Affiliates will not be obligated to undertake or continue any Research or Development activities with respect to any Product if such Party (or any of its Affiliates) reasonably determines that performance of such Research or Development activity would violate Applicable Law or infringe or misappropriate a Third Party’s intellectual property.
3.5.    Follow-On Products.  At any time during the Co-Co Agreement Term, either Party may propose to the other Party, through the JRC, to designate a Follow-On Product as an additional Shared Product under this Agreement. The JSC, taking into consideration the recommendations of the JRC and in consultation with the JDC, shall discuss and determine whether to designate such Follow-On Product as an additional Shared Product under this Agreement. Effective as of any such determination by the JSC, such Follow-On Product shall be deemed a Shared Product for all purposes under this Agreement. Notwithstanding anything to the contrary in this Agreement, any decision to designate a Follow-On Product as an additional Shared Product under this Agreement shall be made only by mutual agreement of the Parties through the JSC, and shall not be subject to any Third Party dispute resolution. 
32

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

3.6.    Additional [***] Targets.  This Agreement constitutes the Joint Development and Commercialization Agreement for each of [***].  The Parties shall conduct Research activities with respect to each of [***] [***] [***] Target that is included as a Collaboration Target in accordance with the Follow-On Research Plan.
ARTICLE 4
MEDICAL AFFAIRS ACTIVITIES.

The Parties, acting through the JDC, will develop and agree upon a global medical affairs plan for the Shared Products that describes the Medical Affairs Activities to be conducted in the Territory, key tactics and strategies for implementing those activities, the relative responsibilities of the Parties and the associated budget for such activities (such plan, the “Medical Affairs Plan” and such budget, the “Medical Affairs Budget”). The Parties will update the Medical Affairs Budget on an annual basis no later than [***], and submit such updated Medical Affairs Budget to the JSC for inclusion in the Integrated Budget. CRISPR will lead and manage Medical Affairs Activities in the United States and Vertex will lead and manage Medical Affairs Activities outside of the United States, in each case, in accordance with the Medical Affairs Plan. The number of MSLs to be deployed in each jurisdiction with respect to a Shared Product will be determined by the JDC promptly after Establishment of POC for such Shared Product.
ARTICLE 5
COMMERCIALIZATION.

5.1.    Responsibilities.  CRISPR shall be the Commercializing lead for the Shared Products in the United States and Vertex shall be the Commercializing lead for the Shared Products outside of the United States. The Commercializing lead, with respect to the United States or outside of the United States, respectively, shall be referred to herein as the “Lead Commercialization Party” for such jurisdiction (as applicable, the “Lead Commercialization Party”). The Lead Commercialization Party with respect to a jurisdiction will have sole responsibility for the conduct of Commercialization activities with respect to each Shared Product in such jurisdiction in its sole discretion, subject to compliance with the approved Global Commercialization Plan, Global Commercialization Budget and Regional Commercialization Plan(s) for such Shared Product, and the provisions of this ARTICLE 5.
5.2.    Commercialization Plans.  The JCC will oversee the Commercialization of the Shared Products by the Parties in the Field in the Territory. No later than [***] prior to the anticipated launch of each Shared Product in the first country in the Territory, the JCC will develop and submit to the JSC for approval a global Commercialization plan (each, a “Global Commercialization Plan”) that sets forth at a high level the Commercialization activities to be undertaken by the 
33

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Parties with respect to the Commercialization of such Shared Product in the Territory. The JCC will update each Global Commercialization Plan on an annual basis (or more frequently as needed) and submit it to the JSC for approval. Each Global Commercialization Plan will include (a) a Global Brand Strategy, (b) a Global Communication Strategy, (c) a Global Market Access and Value Strategy, (d) a Global Pricing Strategy, and (e) a budget for activities conducted under the Global Commercialization Plan (the “Global Commercialization Budget”). In addition, no later than [***] prior to the anticipated launch of each Shared Product in the applicable country, each Lead Commercialization Party will develop one or more regional or country-level Commercialization plans (each, a “Regional Commercialization Plan”) for (a) in the case of CRISPR, the U.S. and (b) in the case of Vertex, the Major [***] Countries. Each Party will submit such Regional Commercialization Plans to the JCC for review and approval. Each Lead Commercialization Party will update its Regional Commercialization Plan(s) on an annual basis (or more frequently as needed) and submit them to the JCC for approval. Each such Regional Commercialization Plan must be consistent at all times with the then-current Global Commercialization Plan (including the Global Commercialization Budget) for the applicable Shared Product.
5.3.    Elements of Global Commercialization Plan.  Without limiting Section 5.2, for each Shared Product, the JCC will develop each of the following strategies and submit them to the JSC for approval as part of the Global Commercialization Plan in accordance with Section 5.2:
5.3.1.    a global brand strategy for such Shared Product in the Territory, including a life cycle plan, launch sequencing, brand vision, positioning, key messaging, concept and imagery, Trademarks (including name and logos) and supporting market research (the “Global Brand Strategy”);
5.3.2.    a global communication strategy for such Shared Product in the Territory, including plans for the coordination of messages between the Parties, public relations, conferences and exhibitions and other external meetings and communications, publications and symposia, congress presence and internet activities (the “Global Communication Strategy”);
5.3.3.    a strategy for the managed markets and global market access for such Shared Product, including payer strategy and account management, global value proposition, evidence plan to support the global value proposition, and the global value dossier, including economic models with respect to the global value proposition as well as a strategy to comply with any government programs, including required pricing submissions and rebates or discounts (the “Global Market Access and Value Strategy”); and
34

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

5.3.4.    a global pricing strategy for such Shared Product (including list price, targeted net pricing, sales-weighted average discounts and rebates, the approach to pricing with different types of accounts and plans, types of discounts and rebates) in the Territory (the “Global Pricing Strategy”), provided that the Lead Commercialization Party in each jurisdiction shall have responsibility for the implementation of such global pricing strategy, including negotiating pricing and reimbursement with governments and private payers, in such jurisdiction.
5.4.    Commercialization Activities.
5.4.1.    Training. The Lead Commercialization Party will prepare training programs and materials for employees and sales representatives with respect to the Shared Products in its respective jurisdiction, with the goal of ensuring compliance with all Applicable Laws and each Party’s compliance policies. The Lead Commercialization Party will be solely responsible for training its employees and sales representatives in accordance with such training program, consistent with the Global Communication Strategy.
5.4.2.    Trademarks. The JCC will select one or more product Trademarks for each Shared Product throughout the world consistent with the applicable Global Brand Strategy. Each Shared Product will be promoted and sold in the Territory under the applicable Trademarks.
5.4.3.    Field Sales. The Lead Commercialization Party will have the sole right to promote the Shared Products (including performing sales calls) in its respective jurisdiction. 
5.4.4.    Distribution and Patient Services. The Lead Commercialization Party will be responsible for distribution and patient services for each Shared Product in its respective jurisdiction, including contracting with applicable service providers, such activities to be determined by the Lead Commercialization Party and included in the Regional Commercialization Plan(s) for such Shared Product.
5.4.5.    Booking Sales; Distribution. The Lead Commercialization Party will have the sole right to invoice, sell and book all sales of each Shared Product in its respective jurisdiction and will be responsible for warehousing and distributing such Shared Product in its respective jurisdiction. 
5.5.    Diligence.  CRISPR will use Commercially Reasonable Efforts to [***] the [***] in the [***]. Vertex will use Commercially Reasonable Efforts to [***] the [***] in the Major [***] Countries. Each Party and its Affiliates will conduct its Commercialization activities in compliance with Applicable Law and the relevant 
35

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Global Commercialization Plan. Notwithstanding anything to the contrary contained herein, a Party or its Affiliates will not be obligated to undertake or continue any Commercialization activities with respect to any Shared Product if such Party (or any of its Affiliates) reasonably determines that performance of such Commercialization activity would violate Applicable Law or infringe or misappropriate a Third Party’s intellectual property. 
ARTICLE 6
MANUFACTURING

6.1.    Manufacturing [***].  During the period starting on the Effective Date and ending on the date that is [***] days after the Effective Date (the “[***]”), CRISPR shall cooperate with Vertex to [***], provided that [***], (b) [***], provided that, [***], and (c) [***].
6.2.    Manufacturing Working Group.  After the Effective Date, the JMC will establish a manufacturing working group (the “Manufacturing Working Group”) to operationalize the Manufacture of the Products in accordance with a global manufacturing plan (the “Global Manufacturing Plan”), including the corresponding budget (the “Manufacturing Budget”), to be prepared by the Manufacturing Working Group within [***] days after the Effective Date and shall be approved by the JMC thereafter. The JMC will select the members of the Manufacturing Working Group as provided in Section 2.5.2(a) and in this Section 6.2.  Unless otherwise mutually approved by the Parties in writing:  (x) [***] will be the lead party on Manufacturing matters; provided that at all times at least [***]% of the members of the Manufacturing Working Group will be [***]representatives; (y) the leader of the Manufacturing Working Group will act as the Manufacturing Lead on the Project Team; and (z) a majority of the members of the Manufacturing Working Group shall be dedicated to the Manufacture of the Products under this Agreement on a full-time basis, unless otherwise mutually agreed by the Parties in writing; provided, however, that any member of the Manufacturing Working Group who is not dedicated to the Manufacture of the Products under this Agreement on a full-time basis must be sufficiently dedicated to such Manufacture to permit such person to be reasonably and consistently available to participate in the activities of the Manufacturing Working Group.  The Manufacturing Working Group will report to the JMC, and will collaborate with the other functions on the Project Team. The Manufacturing Working Group’s responsibilities will include: (a) on an [***] basis (or more frequently as needed), preparing updates to the Global Manufacturing Plan, including the Manufacturing Budget, and submitting such updates to the JMC for review, discussion and approval in accordance with Section 2.5.2(i); (b) developing plans to transfer Manufacturing-related Know-How between the Parties as needed to facilitate the Manufacture of the Products; (c) establishing standards applicable to each Party’s Manufacturing activities and reviewing each 
36

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Party’s performance against such standards; (d) conducting technical reviews; (e) making recommendations to the JMC regarding capacity planning, supply plans and supply continuity planning for the Products; (f) making recommendations to the JMC regarding the Manufacturing process for each Shared Product and any changes thereto; (g) sharing planning and budgeting information with the JMC, the JDC and JCC; (h) reviewing and sharing the results of regulatory and environmental, health and safety inspections and audits related to the Manufacture of the Products with the JMC; (i) managing CMOs conducting Manufacturing activities with respect to the Products and (j) conducting any technology transfer approved by the JMC and in accordance with Section 6.4. The Manufacturing Working Group shall use good faith efforts to reach consensus on the matters for which it is responsible, with each Party’s representatives on the Manufacturing Working Group having collectively one vote; provided that if, despite the use of such good faith efforts for a reasonable period of time (taking into account the nature of the relevant dispute) the Parties representatives are unable to reach consensus on a given matter and such matter does not require the JMC’s approval, [***] [***]; provided that [***]. 
6.3.    Responsibilities.  The Parties, in accordance with the allocation of responsibilities determined by the JMC, shall be responsible for Manufacturing or having Manufactured all pre-clinical, clinical and commercial supplies of the Products in accordance with the Global Manufacturing Plan and subject to the Manufacturing Budget, subject to the oversight of the Manufacturing Working Group and the JMC in consultation with the JDC or JCC, as applicable. The Party responsible for conducting activities under the Global Manufacturing Plan will be responsible for determining how to carry out the day-to-day operations with respect to such activities; provided such activities are conducted in accordance with the Global Manufacturing Plan, Manufacturing Working Group guidance and strategy and all Applicable Laws. The Parties, acting through the Manufacturing Working Group, will ensure the process for Manufacturing a Shared Product [***]. [***] will be responsible for contracting with any CMO with respect to the Manufacture of the Shared Products. If [***] determines to build out its own Manufacturing site, it shall so notify the JMC, and the JMC will determine whether to use such Manufacturing site for the Manufacture of the Products under this Agreement. If the JMC determines to use [***] Manufacturing site for the Manufacture of any Product under this Agreement, [***] will use Commercially Reasonable Efforts to ensure that such Manufacturing site contains reasonably adequate equipment and space dedicated to such Product. For clarity, if the JMC does not initially determine to use [***] Manufacturing site for the Manufacture of any Product under this Agreement, it may at any time thereafter determine to do so, provided that such Manufacturing site contains reasonably adequate equipment and space dedicated to such Product.
6.4.    Sharing of Manufacturing Information.  Subject to this Section 6.4, each Party shall, upon the other Party’s request, provide to such other Party such information 
37

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

as may be requested by such other Party with respect to the Manufacture of any Product under this Agreement for Development, Commercialization or Manufacturing purposes. Without limiting the foregoing, each Party will, within [***] Business Days of the other Party’s request, provide to the requesting Party any information requested with respect to the non-requesting Party’s Manufacturing activities, including site qualification and scale-up activities. Each Party shall, and shall cause its Affiliates to, [***]. Notwithstanding the foregoing, if the JMC determines that a CMO will Manufacture the Products, [***] shall directly transfer to such CMO any information Controlled by and in the possession of [***] or its Affiliate and reasonably necessary or useful to enable the Manufacture of such Products, provided that such transfer obligation shall not limit [***] obligations to transfer information directly to [***] pursuant to this Section 6.4.
6.5.    CMO Agreements.  Each Party will have the right to review and approve the terms of any agreement, including quality agreements, to be entered into between the other Party and a CMO or a contract testing facility with respect to the Manufacture of any Product, or any intermediate thereof, under this Agreement. No such agreement with a CMO or contract testing facility shall be entered into by a Party without the prior approval of the other Party. 
ARTICLE 7
FINANCIAL TERMS; ALLOCATION OF NET PROFIT AND NET LOSS

7.1.    Upfront Payments. Within four Business Days after the Effective Date, Vertex shall pay to CRISPR a non-refundable, non-creditable, upfront payment in the amount of Seven Million Dollars ($7,000,000). For clarity, CRISPR is solely responsible for all costs and expenses incurred by CRISPR or its Affiliates in connection with the Shared Products prior to the Effective Date.
7.2.    Milestone Payment. Upon [***], Vertex will make a one-time, non-refundable, non-creditable payment to CRISPR of [***] ($[***]) within [***] days of receipt by Vertex of an invoice for such payment from CRISPR.
7.3.    Allocation.  Starting [***], and continuing through the Co-Co Agreement Term, each Party will be entitled to [***] or will bear [***], as applicable. Each Party will be solely responsible for any Program Expenses incurred by such Party between the Effective Date and [***], 2018. If either Party elects to Opt-Out (as defined below), the [***].
7.4.    Calculation.  [***].
7.5.    Payment of Expenses; Summary Statements. Subject to reconciliation as provided in Section 7.6, the Party initially incurring Program Expenses will be responsible for and pay for all such Program Expenses so incurred. Each Party 
38

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

will maintain the books and records referred to in Section 7.8. Each Party will accrue all Program Expenses, Sublicense Revenue and Net Sales in accordance with the terms and conditions hereof and in accordance with GAAP, provided that all Out-of-Pocket Costs under this Agreement will be deemed accrued at the time of invoice for purposes of the calculation and reconciliation of Net Profit or Net Loss under this Agreement. Within [***] Business Days after the end of each Calendar Quarter, each Party will submit to the other a written report reflecting the accrual of Program Expenses, Sublicense Revenue and Net Sales during the just-ended Calendar Quarter, except that each Party’s submission for the last month of such Calendar Quarter will be a good faith estimate and not actual amounts (each, a “Summary Statement”). Within [***] days after the end of each Calendar Quarter, each Party will submit to the other an updated Summary Statement reflecting the actual accrual of Program Expenses, Sublicense Revenue and Net Sales for the last month of such Calendar Quarter, which Summary Statement will be certified as true and accurate by a representative of such Party that is a Vice President of Finance or more senior representative. Each Summary Statement (after the initial Summary Statement) will reflect an adjustment for the actual amount of the previous Calendar Quarter as needed, provided that, if, prior to preparation of a Summary Statement in accordance with the preceding sentence, a Party discovers that actual Program Expenses, Sublicense Revenue or Net Sales have deviated materially from any non-binding, good faith estimate of such Program Expenses, Sublicense Revenue or Net Sales submitted to the other Party in accordance with this Section 7.5 (including any deviation in any single Expense or in aggregate Sublicense Revenue or aggregate Net Sales, in each case, of more than $[***]), then such Party shall promptly notify the other Party of such deviation in advance of delivery of such Summary Statement. Any reporting and reconciliation of variances between estimated and actual Expenses may be delayed by a Calendar Quarter as reasonably necessary in light of a Party’s internal reporting procedures. The Parties’ respective Summary Statements will serve as the basis of the Reconciliation Reports prepared by [***] pursuant to Section 7.6. The Parties’ respective finance departments, coordinated by the JDC, or JCC, as appropriate, will meet at least once per [***], or as otherwise mutually agreed by the Parties, to discuss any questions or issues arising from the Summary Statements, including the basis for the accrual of specific Program Expenses, review budgets and forecasts, and discuss reconciliation and reporting procedures.
7.6.    Reconciliation.  [***] will prepare a reconciliation report, as soon as practicable after the receipt of [***] updated Summary Statement, but in any event within [***] days after the end of each Calendar Quarter, accompanied by reasonable supporting documents and calculations sufficient to support each Party’s financial reporting obligations, independent auditor requirements and obligations under the Sarbanes-Oxley Act, which reconciles the amounts accrued and reported in each Party’s Summary Statement during such Calendar Quarter and the share of the Net Profits and Net Losses to be allocated to each of the Parties for such Calendar Quarter in accordance with Section 7.3 (such report, the “Reconciliation 
39

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Report”).  Payment to reconcile Net Profit or Net Loss, as applicable, shall be made by the owing Party to the other Party within [***] days after such Reconciliation Report is complete. 
7.7.    Cost Overruns.  If a Party’s Research Costs, Development Costs, Manufacturing Costs, Medical Affairs Costs or Commercialization Costs in any Calendar Year are likely to exceed those set forth in the Research Budget, Development Budget, Manufacturing Budget, Medical Affairs Budget or Global Commercialization Budgets, as applicable, for all of its activities under the Follow-On Research Plan, Global Development Plan, Global Manufacturing Plan, Medical Affairs Plan or  Global Commercialization Plans, as applicable, in such Calendar Year by [***], Development Budget, Manufacturing Budget, Medical Affairs Budget or Global Commercialization Budgets, as applicable, such Party will provide the other Party with an explanation for such excess Expenses, and such excess Expenses will be included in the Research Costs, Development Costs, Manufacturing Costs, Medical Affairs Costs or Commercialization Costs, as applicable, and, beginning [***], shared by the Parties as provided herein. To the extent a Party’s Research Costs, Development Costs, Manufacturing Costs, Medical Affairs Costs or Commercialization Costs, as applicable, exceed those set forth in the Research Budget, Development Budget, Manufacturing Budget, Medical Affairs Budget or Global Commercialization Budgets, [***]. 
7.8.    Books and Records. Each Party will keep and maintain accurate and complete records regarding Program Expenses, Sublicense Revenue and Net Sales, during the three preceding Calendar Years. Upon [***] days’ prior written notice from the Auditing Party, the Audited Party will permit an independent certified public accounting firm of internationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine the relevant books and records of the Audited Party and its Affiliates, as may be reasonably necessary to verify the Summary Statements and Reconciliation Reports. An examination by the Auditing Party under this Section 7.8 will occur not more than once in any Calendar Year and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] months before the date of the request. The accounting firm will be provided access to such books and records at the Audited Party’s facility or facilities where such books and records are normally kept and such examination will be conducted during the Audited Party’s normal business hours. The Audited Party may require the accounting firm to sign a customary non-disclosure agreement before providing the accounting firm access to its facilities or records. Upon completion of the audit, the accounting firm will provide both the Auditing Party and the Audited Party a written report disclosing whether the applicable Summary Statements and Reconciliation Reports are correct or incorrect and the specific details concerning any discrepancies. No other information will be provided to the Auditing Party. If the report or information submitted by the Audited Party results in an underpayment or overpayment, the Party owing underpaid or overpaid amount will promptly pay 
40

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

such amount to the other Party, and if, as a result of such inaccurate report or information, such amount is more than five percent of the amount that was owed, the Audited Party will reimburse the Auditing Party for the reasonable expense incurred by the Auditing Party in connection with the audit.
7.9.    Payment Method; Currency. 
7.9.1.    All payments under this Agreement will be paid in U.S. Dollars, by wire transfer (a) in the case of payments to [***], by [***] to an account of [***] designated by [***] (which account CRISPR may update from time to time in writing) and (b) in the case of payments to [***], by [***]. to an account of [***] designated by [***] (which account [***] may update from time to time in writing).
7.9.2.    If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any calculations to be performed under this Agreement are denoted in a currency other than U.S. Dollars, then such amounts will be converted to their U.S. Dollar equivalent using the [***] of the official rate of exchange of such domestic currency as quoted by [***], for the Calendar Quarter for which the payment is made.
7.10.    Late Payment.  Any undisputed payments or portions thereof due hereunder that are not paid when due will accrue interest from the date due until paid at an annual rate equal to [***] plus [***] percent (or the maximum allowed by Applicable Law, if less).
7.11.    Payments To / From [***].  Notwithstanding anything to the contrary set forth in this Agreement, (i) any payments to be made by any [***] under this Agreement shall be made by [***] only; and (ii) any payments to be made to any [***] under this Agreement shall be made to [***] only.
ARTICLE 8
ADVERSE EVENTS

8.1.    Pharmacovigilance Agreement. [***] shall be responsible for all pharmacovigilance activities for the Shared Products in the Territory. Within [***] days after the Effective Date, the Parties will negotiate in good faith and will set forth in a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) mutually agreed terms and conditions for the processes and procedures for sharing safety information with respect to the Shared Products that are customary for agreements of this type. The Pharmacovigilance Agreement will include provisions establishing a joint disease area safety team led by [***] to oversee the conduct of the Parties’ activities under the Pharmacovigilance Agreement and to coordinate the Parties’ interactions with respect to pharmacovigilance activities.
41

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

8.2.    Global Safety Database. [***] will establish and maintain the global database of safety information for each Shared Product (each, a “Global Safety Database”), including adverse events and pregnancy reports for each Shared Product, which will be used for regulatory reporting and responses to safety queries from Regulatory Authorities by both Parties. [***] will, and will cause its Affiliates to, transfer all adverse events information in its or their possession or control to the Global Safety Database within a mutually agreed period of time that provides Vertex with sufficient time for the preparation of required regulatory submissions.
8.3.    Risk Management and Signal Detection Activities. [***] shall be primarily responsible for all signal detection and risk management activities for the Shared Products. These signal detection activities shall include, but are not limited to, proactive review and evaluation of all safety information from the applicable Global Safety Database (including Individual Case Safety Reports and aggregate safety information) and other sources (including the clinical trial databases, non-clinical data, and medical or scientific literature).
8.4.    Access to Safety Information.  The Parties will arrange for [***] to [***], with a format and periodicity agreed upon by both Parties. In response to [***] from [***], [***] will [***] to [***] within [***] Business Days of a request. In addition, [***] shall [***] to [***].
ARTICLE 9
SUBCONTRACTING

Each Party may subcontract the performance of any activities undertaken by such Party in accordance with the Global Development Plan, the Follow-On Research Plan, the Medical Affairs Plan, any Global Commercialization Plan or any Regional Commercialization Plan to one or more Third Parties (each such Third Party, a “Subcontractor”) pursuant to a written agreement (a “Subcontract”) in compliance with the terms of this Agreement and the Quality Agreement. Notwithstanding the foregoing, if either Party desires to subcontract any such activities, it will first discuss the matter with the other Party and reasonably consider using the other Party for such subcontracted activities, taking into account the capabilities of the other Party and potential impact on Expenses, as a potential alternative to subcontracting such activities to a Third Party. If, following such discussion, a Party still desires to subcontract the performance of any such activity to one or more Third Parties, it may proceed to do so, subject to Section 2.3.2(v), Section 2.4.2(k) or Section 2.5.2(o), as applicable, in the case of any such subcontract that the subcontracting Party reasonably anticipates will entail payments to the Subcontractor in excess of $[***] with respect to the subcontracted activities under this Agreement. 
ARTICLE 10
LICENSE GRANTS
42

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

10.1.    Acknowledgment of Option Exercise.  Each Party acknowledges and agrees that, notwithstanding anything to the contrary in the Collaboration Agreement, effective as of the execution of this Agreement, Vertex is deemed to have exercised [***], without any further action on the part of either Party, [***].
10.2.    License Grants to Vertex. 
10.2.1.    Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, CRISPR and, following the Subsidiary Transfer, the CRISPR Subsidiary, grants to Vertex UK and its Affiliates a co-exclusive (with CRISPR) license under CRISPR’s and its Affiliates’ interest in the Licensed CRISPR Technology, with the right to Sublicense through multiple tiers (subject to Section 10.5), to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Shared Products in the Field in the Territory (such license, the “Exclusive License”). As of the Effective Date, this Exclusive License supersedes and replaces the license grant set forth in Section 5.3.1 of the Collaboration Agreement solely with respect to the Shared Targets, and shall be deemed to be the “Exclusive License” under the Collaboration Agreement with respect to the Shared Targets.
10.2.2.    Research Licenses. Subject to the terms and conditions of this Agreement, CRISPR and, following the Subsidiary Transfer, the CRISPR Subsidiary, grants to Vertex UK and its Affiliates a co-exclusive (with CRISPR) license under CRISPR’s and its Affiliates’ interest in the Licensed CRISPR Technology solely to conduct the activities set forth in the Follow-On Research Plan with respect to Follow-On Products in the Field in the Territory.
10.2.3.    License Conditions; Limitations. Subject to Section 10.7.2, any rights and obligations hereunder, including the rights granted pursuant to the Exclusive License, are subject to and limited by any applicable [***] of CRISPR to the extent the provisions of such obligations or agreements are specifically disclosed to Vertex in writing: (a) with respect to [***] under a CRISPR In-License Agreement, prior to (i) the Effective Date, in the case of the Initial Shared Product, and (ii) the date of designation of a Follow-On Product as a Shared Product, in the case of any other Shared Product; and (b) with respect to [***] under a [***] for which CRISPR is the contracting Party, on or prior to the date on which such [***] becomes effective.
10.3.    License Grants to CRISPR. 
10.3.1.    Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, Vertex grants to CRISPR a co-
43

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

exclusive (with Vertex and its Affiliates) license under Vertex’s and its Affiliates’ interest in the Licensed Vertex Technology, with the right to Sublicense through multiple tiers (subject to Section 10.5), to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Shared Products in the Field in the Territory.
10.3.2.    Research Licenses. Subject to the terms and conditions of this Agreement, Vertex grants to CRISPR a co-exclusive (with Vertex and its Affiliates) license under Vertex’s and its Affiliates’ interest in the Licensed Vertex Technology solely to conduct the activities set forth in the Follow-On Research Plan with respect to Follow-On Products in the Field in the Territory. 
10.3.3.    License Conditions; Limitations. Subject to Section 10.7.2, any rights and obligation hereunder are subject to and limited by any applicable [***] of Vertex to the extent the provisions of such obligations or agreements are specifically disclosed to CRISPR in writing: (a) with respect to [***] under a Vertex In-License Agreement, prior to (i) the Effective Date, in the case of the Initial Shared Product, and (ii) the date of designation of a Follow-On Product as a Shared Product, in the case of any other Shared Product; and (b) with respect to [***] under a [***] for which Vertex is the contracting Party, on or prior to the date on which such [***] becomes effective.  
10.4.    Licenses to Improvements.  
10.4.1.    Subject to the terms and conditions of this Agreement, CRISPR, and, following the Subsidiary Transfer, to the extent necessary, the CRISPR Subsidiary, hereby grants to Vertex UK and its Affiliates a perpetual, irrevocable, non-exclusive, royalty-free, fully paid-up, worldwide, sublicensable license to all improvements or modifications to the Vertex Background Know-How or Vertex Background Patents, whether or not patentable, that arise in the course of performing activities under the Global Development Plan or the Follow-On Research Plan or in the course of Developing, Manufacturing or Commercializing a Product and are Controlled by CRISPR or its Affiliates to make, have made, use, sell, keep, offer for sale and import products other than Shared Products.
10.4.2.    Subject to the terms and conditions of this Agreement, Vertex hereby grants to CRISPR a perpetual, irrevocable, non-exclusive, royalty-free, fully paid-up, worldwide, sublicensable license to all improvements or modifications to the CRISPR Platform Technology Patents, CRISPR Background Patents [***], Gene Editing System or CRISPR Background Know-How set forth on Schedule F to the Collaboration Agreement (as may be supplemented by mutual written agreement of the Parties from 
44

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

time to time), whether or not patentable, that arise in the course of performing activities under the Global Development Plan or the Follow-On Research Plan or in the course of Developing, Manufacturing or Commercializing a Product and are Controlled by Vertex or its Affiliates to make, have made, use, sell, keep, offer for sale and import products other than Shared Products. 
10.5.    Sublicensing.  Subject to the rights granted or retained by the Parties under this Agreement, either Party may Sublicense (through multiple tiers) to its Affiliates or Third Parties any and all rights granted to it by the other Party or retained by such Party with respect to the Research, Development, Manufacture and Commercialization of Shared Products, provided that neither Party may grant any such Sublicense (other than a Subcontract in accordance with the provisions of ARTICLE 9) in a [***] or [***] without the prior written consent of the other Party; and provided, further, that if either Party intends to Sublicense any such rights in any country, it will discuss the matter with the other Party and in good faith consider using the other Party to conduct any sublicensed activities. If a Party grants any such Sublicense it will remain responsible for its obligations under this Agreement and will be responsible for the performance of the relevant Sublicensee.
10.6.    No Implied Licenses.  All rights in and to Licensed CRISPR Technology not expressly licensed or assigned to Vertex under this Agreement or the Collaboration Agreement are hereby retained by CRISPR or its Affiliates. All rights in and to any Licensed Vertex Technology not expressly licensed to CRISPR under this Agreement or the Collaboration Agreement, are hereby retained by Vertex or its Affiliates. Except as expressly provided in this Agreement or the Collaboration Agreement, no Party will be deemed by estoppel or implication to have granted the other Party any licenses or other right with respect to any intellectual property.
10.7.    Third Party Agreements.
10.7.1.    In-License Agreements. Any financial obligations arising under any CRISPR In-License Agreement or Vertex In-License Agreement as a result of the Development, Manufacture or Commercialization of any Product by either Party, its Affiliates and Sublicensees under this Agreement will be included in [***]. 
10.7.2.    [***].  If a Party believes, in its reasonable judgment, that it may be necessary to obtain rights under any [***] in order [***] such Party will promptly notify the other Party and [***]. Unless otherwise agreed by the Parties in writing, (a) if such [***] [***] and (b) [***] [***]. [***] (each, a “[***]”) [***]. [***], the Parties will [***]. If it is [***] are [***], then the applicable Party shall [***], and the [***] shall be included as [***] under this Agreement. If, within [***] days [***], the 
45

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

applicable Party has not [***], the other Party shall [***], and the [***] shall be included as [***] under this Agreement. If it is [***], then [***], provided that the [***] shall not be [***] and shall not be included as [***] under this Agreement unless otherwise mutually agreed by the Parties in writing. The [***] shall [***], and shall not [***].
10.8.    Trademarks.  The Lead Commercialization Party will own and retain all rights to all filed Trademarks for the Shared Products in their respective jurisdictions, and all goodwill associated with or attached thereto arising out of the use thereof by the Parties, their Affiliates and Sublicensees will inure to the benefit of such Lead Commercialization Party. Each non-Lead Commercialization Party, on behalf of itself and its Affiliates, will assign to the Lead Commercialization Party or its relevant Affiliate all right, title and interest in and to such Shared Product Trademarks and goodwill in the relevant jurisdictions. The non-Lead Commercialization Party will not contest, oppose or challenge the Lead Commercialization Party’s ownership of such Shared Product Trademarks in the relevant jurisdictions. The Lead Commercialization Party will own rights to any Internet domain names incorporating any Trademark for the Shared Products, or any variation or part of any such Trademark, as its URL address or any part of such address in the applicable jurisdictions. The Lead Commercialization Party will use Commercially Reasonable Efforts to register, maintain and enforce the Trademarks for the Shared Products in the relevant jurisdictions. Notwithstanding anything to the contrary, if a single Trademark is used throughout the Territory with respect to a Shared Product, the Parties will mutually agree upon the ownership of such Shared Product Trademark in the Territory.   
ARTICLE 11
INTELLECTUAL PROPERTY

The terms of the Collaboration Agreement will apply with respect to any and all Know-How and Patents discovered, developed, invented or created in connection with activities under this Agreement.  
ARTICLE 12
REPRESENTATIONS AND WARRANTIES

12.1.    Representations and Warranties of Vertex. Vertex hereby represents and warrants to CRISPR, as of the Effective Date, that: 
12.1.1.    each of Vertex Parent and Vertex UK is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
46

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

12.1.2.    each of Vertex Parent and Vertex UK (a) has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;
12.1.3.    this Agreement has been duly executed and delivered on behalf of each of Vertex Parent and Vertex UK, and constitutes a legal, valid and binding obligation, enforceable against each of Vertex Parent and Vertex UK in accordance with the terms hereof;
12.1.4.    the execution, delivery and performance of this Agreement by each of Vertex Parent and Vertex UK will not constitute a default under or conflict with any agreement, instrument or understanding, oral or written, to which either entity is a party or by which either entity is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over Vertex Parent or Vertex UK; and
12.1.5.    each of Vertex Parent and Vertex UK has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities required to be obtained by it in connection with the execution and delivery of this Agreement.
12.2.    Representations and Warranties of CRISPR.  Each of the CRISPR Entities, jointly and severally, hereby represents and warrants to Vertex, as of the Effective Date, except as set forth on Schedule G, that:
12.2.1.    each of CRISPR AG, CRISPR Inc., CRISPR UK and Tracr is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
12.2.2.    each of CRISPR AG, CRISPR Inc., CRISPR UK and Tracr (a) has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;
12.2.3.    this Agreement has been duly executed and delivered on behalf of CRISPR, and constitutes a legal, valid and binding obligation, enforceable against it in accordance with the terms hereof;
12.2.4.    the execution, delivery and performance of this Agreement by CRISPR will not constitute a default under or conflict with any agreement, 
47

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

instrument or understanding, oral or written, to which it is a party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; 
12.2.5.    CRISPR has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities required to be obtained by CRISPR in connection with the execution and delivery of this Agreement;
12.2.6.    the Licensed CRISPR Technology constitutes all of the Patents and Know-How Controlled by CRISPR that are necessary to Research, Develop, Manufacture or Commercialize the Shared Products contemplated under this Agreement in the Field in the Territory;
12.2.7.    CRISPR is the sole and exclusive owner or exclusive licensee of the CRISPR Platform Technology Patents and CRISPR Background Patents, all of which are free and clear of any liens, charges and encumbrances, and, as of the Effective Date, neither any license granted by CRISPR to any Third Party, nor any license granted by any Third Party to CRISPR, conflicts with the license grants to Vertex hereunder, and CRISPR is entitled to grant all rights and licenses (or sublicenses, as the case may be) under such Patents it purports to grant to Vertex under this Agreement;
12.2.8.    [***], the Research, Development, Manufacture, use, sale, offer for sale, supply or importation by [***]
12.2.9.    there are no judgments or settlements against or owed by [***], pending or threatened claims or litigation, in either case relating to the Licensed CRISPR Technology; 
12.2.10.    the CRISPR Platform Technology Patents and CRISPR Background Patents are, or, upon issuance, will be, [***], [***], [***] and
12.2.11.    [***], there are no Manufacturing capacity or Manufacturing process issues that [***] on the Manufacture of the Products.
12.3.    CRISPR Covenants.  Each of the CRISPR Entities, jointly and severally, hereby covenants to Vertex that, except as expressly permitted under this Agreement:
12.3.1.    CRISPR will maintain and not breach any CRISPR In-License Agreements or [***] that provide a grant of rights from such Third Party to CRISPR that are Controlled by CRISPR and are licensed or may become subject to a license from CRISPR to Vertex for the Shared Products under this Agreement; 
48

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

12.3.2.    CRISPR will promptly notify Vertex of any material breach by one or more CRISPR Entities or a Third Party of any CRISPR In-License Agreements or [***] that provides a grant of rights from such Third Party to one or more CRISPR Entities and are licensed from CRISPR to Vertex under this Agreement, and in the event of a breach by [***], will [***]. CRISPR will [***] as soon as possible, but in no event later than the date on which [***];
12.3.3.    it will not amend, modify or terminate any CRISPR In-License Agreement or [***] in a manner that would have an adverse effect on Vertex’s rights hereunder without first obtaining Vertex’s written consent, which consent may be withheld in Vertex’s sole discretion;
12.3.4.    it will not enter into any new agreement or other obligation with any Third Party, or amend an existing agreement with a Third Party, in each case that adversely restricts, limits or encumbers the rights granted to Vertex under this Agreement or the additional rights;
12.3.5.    it will not, and will cause its Affiliates not to (a) license, sell, assign or otherwise transfer to any Person any Licensed CRISPR Technology (or agree to do any of the foregoing), except as will not adversely restrict, limit or encumber the rights granted to Vertex under this Agreement, or (b) incur or permit to exist, with respect to any Licensed CRISPR Technology, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other restriction (including in connection with any indebtedness);
12.3.6.    it will use Commercially Reasonable Efforts to obtain and maintain the requisite resources and expertise to perform its obligations hereunder;
12.3.7.    all employees and Subcontractors of CRISPR performing Research or Development activities hereunder on behalf of CRISPR will be obligated to assign to CRISPR all right, title and interest in and to any inventions developed by them, whether or not patentable, or, solely with respect to Subcontractors, grant exclusive license rights to CRISPR with a right to grant sublicenses through multiple tiers;
12.3.8.    it will not engage, in any capacity in connection with this Agreement, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FD&C Act or is subject to any such similar sanction; and
12.3.9.    CRISPR will inform Vertex in writing promptly if it or any Person engaged by CRISPR or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FD&C Act, or if 
49

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

any action, suit, claim, investigation or legal or administrative proceeding is pending or, to CRISPR’s Knowledge, is threatened, relating to the debarment or conviction of CRISPR, any of its Affiliates or any such Person performing services hereunder or thereunder.
12.4.    Vertex Covenants. Vertex hereby covenants to CRISPR that, except as expressly permitted under this Agreement:
12.4.1.    it will use Commercially Reasonable Efforts to obtain and maintain the requisite resources and expertise to perform its obligations hereunder;
12.4.2.    Vertex will not engage, in any capacity in connection with this Agreement any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FD&C Act or is subject to any such similar sanction; and
12.4.3.    Vertex will inform CRISPR in writing promptly if it or any Person engaged by Vertex or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FD&C Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Vertex’s knowledge, is threatened, relating to the debarment or conviction of CRISPR, any of its Affiliates or any such Person performing services hereunder or thereunder.
12.5.    Disclaimer.  Except as otherwise expressly set forth in this Agreement, neither Party nor its Affiliates makes any representation or extends any warranty of any kind, either express or implied, including any warranty of merchantability or fitness for a particular purpose. Vertex and CRISPR understand that each Product is the subject of ongoing Research and Development and that neither Party can assure the safety, usefulness or commercial or technical viability of any Product.
12.6.    [***].  Notwithstanding anything to the contrary in this Agreement, if it is [***] that [***] has [***] (a “[***]”), then (a) if [***] shall [***] The Parties acknowledge and agree that notwithstanding anything to the contrary in this Agreement, (i) a [***], and [***] or the [***] and (ii) [***].
ARTICLE 13
INDEMNIFICATION; INSURANCE

13.1.    Indemnification by Vertex. Vertex will indemnify, defend and hold harmless each CRISPR Indemnified Party from and against any and all Liability that the CRISPR Indemnified Party may be required to pay to one or more Third Parties to the extent resulting from or arising out of: 
50

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

13.1.1.    [***];
13.1.2.    [***];
except, in each case, to the extent CRISPR is required to indemnify Vertex pursuant to Section 13.2.
13.2.    Indemnification by CRISPR. Each CRISPR Entity will jointly and severally indemnify, defend and hold harmless each Vertex Indemnified Party from and against any and all Liabilities that the Vertex Indemnified Party may be required to pay to one or more Third Parties to the extent resulting from or arising out of:
13.2.1.    [***];
13.2.2.    [***];
except, in each case, to the extent Vertex is required to indemnify CRISPR pursuant to Section 13.1.
13.3.    Procedure.  Each Party will notify the other Party in writing if it becomes aware of a claim for which indemnification may be sought hereunder. In case any proceeding (including any governmental investigation) will be instituted involving any Indemnified Party, such Indemnified Party will give prompt written notice of the indemnity claim to the Indemnifying Party and provide a copy to the Indemnifying Party of any complaint, summons or other written or verbal notice that the Indemnified Party receives in connection with any such claim. An Indemnified Party’s failure to deliver written notice will relieve the Indemnifying Party of liability to the Indemnified Party under this ARTICLE 13 only to the extent such delay is prejudicial to the Indemnifying Party’s ability to defend such claim. Provided that the Indemnifying Party is not contesting the indemnity obligation, the Indemnified Party will permit the Indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated settlement or otherwise and any failure to contest prior to assuming control will be deemed to be an admission of the obligation to indemnify. The Indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim and will not settle or otherwise resolve such claim without the Indemnified Party’s prior written consent, which will not be withheld, delayed or conditioned unreasonably, other than settlements only involving the payment of monetary awards for which the Indemnifying Party will be fully-responsible. The Indemnified Party will cooperate with the Indemnifying Party in such Party’s defense of any claim for which indemnity is sought under this Agreement, at the Indemnifying Party’s sole cost and expense.
13.4.    Other Third Party Claims.  If a Third Party brings a claim of any nature arising out of [***] other than [***], the [***] will [***]. [***] will [***]. The [***] will [***]. The [***]. If [***].
51

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

13.5.    Insurance.  
13.5.1.    Coverage. From and after the Effective Date, each Party will, at its sole cost and expense, procure and maintain the following policies, each naming the other Party and its Indemnified Parties as additional insureds:
(a)    [***] in amounts not less than $[***] annual aggregate; 
(b)    [***] coverage in amounts not less than $[***]; 
(c)    [***] in amounts not less than $[***] per incident and $[***] annual aggregate, which policy shall include [***], as applicable, and for [***]; and
(d)    [***] (also called [***]) in amounts not less than $[***] per claim and annual aggregate, covering [***]. 
Each such policy will be [***].
13.5.2.    Evidence of Insurance.  Each Party will provide the other Party with evidence of the insurance required under this Section 13.5 upon the other Party’s request. Each Party will provide the other Party with notice at least 30 days prior to the cancellation, non-renewal or material change in such insurance. The cancelling or non-renewing Party will obtain replacement insurance providing comparable coverage prior to the expiration of such 30-day period.
13.5.3.    Post-Termination Obligations. Each Party will maintain the insurance required under this Section 13.5 beyond the expiration or termination of this Agreement for a reasonable period after the period during which either Party or its Affiliates or Sublicensees is Developing or Commercializing any Product, which in no event will be less than five years.
13.5.4.    Affiliates, Sublicensees and Distributors. Each Party will (i) ensure that all applicable Affiliates of such Party are covered under such Party’s insurance policies as described in Section 13.5.1 and (ii) require all of its Sublicensees and Distributors to comply with the provisions and obligations under this Section 13.5 as if such entity were such Party. 
13.5.5.    No Limitation. The minimum amounts of insurance coverage required under this Section 13.5 will not be construed to create a limit of liability with respect to a Party’s indemnification obligations under Section 13.1 or 13.2, as applicable, or with respect to such Party’s share of any Liabilities under Section 13.4.
52

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

13.5.6.    Self-Insurance.  Notwithstanding the foregoing, [***] may self-insure to the extent that it self-insures for its other activities.
13.6.    Limitation of Consequential Damages.  Except for (a) claims of a Third Party that are subject to indemnification under this ARTICLE 13, (b) claims arising out of a Party’s willful misconduct, or (c) a Party’s breach of ARTICLE 15, neither Party nor any of its Affiliates will be liable to the other Party or its Affiliates for any incidental, consequential, special, punitive or other indirect damages or lost or imputed profits or royalties, lost data or cost of procurement of substitute goods or services, whether liability is asserted in contract, tort (including negligence and strict product liability), indemnity or contribution, and irrespective of whether that Party or any representative of that Party has been advised of, or otherwise might have anticipated the possibility of, any such loss or damage.
ARTICLE 14
TERM; TERMINATION

14.1.    Co-Co Agreement Term; Expiration.  This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 14, will continue in full force and effect until there is no longer any Global Development Plan or Global Commercialization Plan contemplating Development or Commercialization of the Shared Products in the Territory.
14.2.    Termination of the Agreement.
14.2.1.    Vertex’s Termination for Convenience. Vertex will be entitled to terminate this Agreement for convenience, in its entirety or with respect to one or more Shared Product(s), by providing CRISPR 90 days’ written notice of such termination; provided, however, that if any termination under this Section 14.2.1 with respect to a Shared Product occurs after such Shared Product has received Marketing Approval, Vertex will provide CRISPR no less than 270 days’ written notice of such termination.
14.2.2.    Termination for Material Breach.
(a)    Vertex’s Right to Terminate. If CRISPR (or any CRISPR Entity(ies)) is in material breach of this Agreement, then Vertex may deliver notice of such material breach to CRISPR. If the breach is curable, CRISPR will have [***] days from the receipt of such notice to cure such breach (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within [***] Business Days following receipt of such notice). If either CRISPR fails to cure such breach within such [***]-day or [***]-Business Day period, as 
53

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

applicable, or the breach is not subject to cure, Vertex in its sole discretion may either (i) terminate this Agreement (A) if such breach relates solely to a particular Shared Product, with respect to the Shared Product affected by such breach or (B) if such breach relates to this Agreement as a whole, in its entirety, by providing written notice to CRISPR or (ii) elect to exercise the alternative remedy provisions set forth in Section 14.5 (in lieu of termination).
(b)    CRISPR’s Right to Terminate. If Vertex is in material breach of this Agreement, then CRISPR may deliver notice of such material breach to Vertex. If the breach is curable, Vertex will have [***] days following receipt of such notice to cure such breach (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within [***] Business Days following receipt of such notice). If Vertex fails to cure such breach within the [***]-day or [***]-Business Day period, as applicable, or the breach is not subject to cure, CRISPR in its sole discretion may either (i) terminate this Agreement (A) if such breach relates solely to a particular Shared Product, with respect to the Shared Product affected by such breach or (B) if such breach relates to this Agreement as a whole, in its entirety, by providing written notice to Vertex or (ii) elect to exercise the alternative remedy provisions set forth in Section 14.5 (in lieu of termination).
(c)    Disputes Regarding Material Breach. Notwithstanding the foregoing, if the Breaching Party in this Section 14.2.2 disputes in good faith the existence, materiality, or failure to cure of any such breach that is not a payment breach, and provides notice to the Non-Breaching Party of such dispute within the relevant cure period, the Non-Breaching Party will not have the right to terminate this Agreement in accordance with this Section 14.2.2, unless and until the relevant dispute has been resolved. It is understood and acknowledged that during the pendency of such dispute, all the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder.
14.2.3.    Termination for Patent Challenge. If a Party (the “Challenging Party”) (A) commences or actively and voluntarily participates in any action or proceeding (including any Patent opposition or re-examination proceeding), or otherwise asserts any claim, challenging or denying the validity or enforceability of any claim of any Patent that is licensed to the Challenging Party under this Agreement or (B) actively and voluntarily 
54

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

assists any other Person in bringing or prosecuting any action or proceeding (including any Patent opposition or re-examination proceeding) challenging or denying the validity or enforceability of any claim of any Patent that is licensed to the Challenging Party under this Agreement by the other Party (the “Non-Challenging Party”) (each of (A) and (B), a “Patent Challenge”), then, to the extent permitted by Applicable Law, the Non-Challenging Party shall have the right, in its sole discretion, to give notice to the Challenging Party that the Non-Challenging Party may terminate the license(s) granted under such Patent to the Challenging Party  [***] days following such notice, and, unless the Challenging Party withdraws or causes to be withdrawn all such challenge(s), or in the case of ex-parte proceedings, multi-party proceedings, or other Patent Challenges that the Challenging Party does not have the power to unilaterally withdraw or cause to be withdrawn, the Challenging Party ceases assisting any other party to such Patent Challenge and, to the extent the Challenging Party is a party to such Patent Challenge, it withdraws from such Patent Challenge within such [***]-day period, the Non-Challenging Party shall have the right to deem the Challenging Party to have exercised an Opt-Out with respect to any Shared Product(s) Covered by a Patent that is the subject of such Patent Challenge, by providing written notice thereof to the Challenging Party, in which case the provisions of Section 14.3 shall apply; provided, however, [***].   The foregoing right of the Non-Challenging Party shall not apply with respect to any Patent Challenge where the Patent Challenge is made in defense of an assertion of the relevant Patent that is first brought by the Non-Challenging Party against the Challenging Party.  For the avoidance of doubt, any participation by the Challenging Party or its employees in any claim, challenge or proceeding in response to a subpoena or as required under a pre-existing agreement between the Challenging Party’s employee(s) or consultant(s) and their prior employer(s) shall not constitute active and voluntary participation or assistance and shall not give rise to the Non-Challenging Party’s right to deem the Challenging Party as having exercised an Opt-Out with respect to any Shared Product hereunder.
14.2.4.    Termination for Insolvency. If CRISPR (or any CRISPR Entity(ies)) undergoes any Insolvency Event, then Vertex may terminate this Agreement in its entirety effective immediately upon written notice to CRISPR. If an Insolvency Event occurs with respect to CRISPR (or any CRISPR Entity(ies)):
(a)    All rights and licenses now or hereafter granted by CRISPR to Vertex under or pursuant to this Agreement, including, for the avoidance of doubt, any Exclusive Licenses, are, for all purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights 
55

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

to “intellectual property” as defined in the U.S. Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to CRISPR (or any CRISPR Entity(ies)), CRISPR agrees that Vertex, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. CRISPR will, during the Co-Co Agreement Term, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all intellectual property licensed under this Agreement. Each Party acknowledges and agrees that “embodiments” of intellectual property within the meaning of Section 365(n) include laboratory notebooks, cell lines, product samples and inventory, research studies and data, all Regulatory Approvals (and all applications for Regulatory Approval) and rights of reference therein, the Licensed CRISPR Technology and all information related to the Licensed CRISPR Technology. If (x) a case under the U.S. Bankruptcy Code is commenced by or against CRISPR (or any CRISPR Entity(ies)), (y) this Agreement is rejected as provided in the U.S. Bankruptcy Code, and (z) Vertex elects to retain its rights hereunder as provided in Section 365(n) of the U.S. Bankruptcy Code, CRISPR (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) will:
(i)    provide to Vertex all such intellectual property (including all embodiments thereof) held by CRISPR and such successors and assigns, or otherwise available to them, immediately upon Vertex’s written request. Whenever CRISPR or any of its successors or assigns provides to Vertex any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 14.2.4(a)(i), Vertex will have the right to perform CRISPR’s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by Vertex will release CRISPR from liability resulting from rejection of the license or the failure to perform such obligations; and
(ii)    not interfere with Vertex’s rights under this Agreement, or any agreement supplemental hereto, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in Section 365(n) of the U.S. Bankruptcy Code.
56

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

(b)    All rights, powers and remedies of Vertex provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the U.S. Bankruptcy Code) in the event of the commencement of a case under the U.S. Bankruptcy Code with respect to CRISPR. The Parties agree that they intend the following rights to extend to the maximum extent permitted by Applicable Law, and to be enforceable under U.S. Bankruptcy Code Section 365(n):
(i)    the right of access to any intellectual property rights (including all embodiments thereof) of CRISPR, or any Third Party with whom CRISPR contracts to perform an obligation of CRISPR under this Agreement, and, in the case of any such Third Party, which is necessary for the Manufacture, use, sale, import or export of Shared Products; and
(ii)    the right to contract directly with any Third Party to complete the contracted work.
14.3.    Opt-Out. 
14.3.1.    On a Shared Product-by-Shared Product basis, after [***], either Party may opt out of this Agreement with respect to such Shared Product (the “Opt-Out Product”) upon [***] days’ notice to the other Party (“Opt-Out”). The other Party shall pay such opting out Party royalties on Net Sales (as defined in the Collaboration Agreement) of such Opt-Out Product (“Opt-Out Royalties”) in accordance with this Section 14.3, and the terms of Sections 7.5.2, 7.5.3, 7.5.4 and 7.5.5 of the Collaboration Agreement shall apply to such royalties, mutatis mutandis. The applicable royalty rates shall be determined in accordance with the table set forth below based on the timing of the Opt-Out notice for the applicable Opt-Out Product. Upon the other Party’s receipt of such notice, all rights and obligations under this Agreement with respect to the Opt-Out Product shall terminate, except for the obligations set forth in this Section 14.3.
57

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

									
	Timing of Opt Out for an Opt-Out Product	Net Sales (in Dollars) for such Opt-Out Product in the Territory
	Opt-Out Royalty Rates as a Percentage (%) of Net Sales of such Opt-Out Product

	[***]	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

14.3.2.    If the opting out Party is CRISPR, the Opt-Out Product shall be deemed a Product (as defined in the Collaboration Agreement) directed to a Collaboration Target other than a [***] under the Collaboration Agreement, and the terms and conditions of the Collaboration Agreement shall apply with respect to the Opt-Out Product, provided that, in lieu of the royalty rates payable under Section 7.5.1 of the Collaboration Agreement Vertex shall pay royalties at the rates set forth in this Section 14.3; and provided, further, that Vertex shall have no obligation to pay to CRISPR any milestone payment under Section 7.3 of the Collaboration Agreement with respect to such Opt-Out Product.
14.3.3.    If the opting out Party is Vertex, the Parties shall negotiate in good faith a termination agreement for the Opt-Out Product, including the obligation to pay royalties as set forth in this Section 14.3 and the following provisions:  
(a)    CRISPR (acting directly or through one or more Affiliates or Sublicensees) will use Commercially Reasonable Efforts to [***] for the [***] in all [***]
(b)    CRISPR (acting directly or through one or more Affiliates or Sublicensees) will use Commercially Reasonable Efforts to [***], the [***] in each [***] where [***]; 
(c)    CRISPR will prepare a Development and Commercialization plan setting forth in reasonable detail (which detail shall be at least sufficient for Vertex to evaluate CRISPR’s compliance with its obligations under this Agreement) CRISPR’s plans for (a) the Development of the Opt-Out Product through [***] and (b) starting upon [***] for the Opt-Out Product and continuing thereafter until the expiration of the applicable Royalty Term, Commercialization of the Opt-Out Product, as appropriate for the 
58

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

stage of the Opt-Out Product, including a launch plan for each [***]; and
(d)    following the first sale of the Opt-Out Product giving rise to Net Sales (as defined in the Collaboration Agreement), within [***] days after the end of each Calendar Quarter, CRISPR will deliver a report to Vertex specifying on a country-by-country basis: [***]. All royalty payments due for each Calendar Quarter will be due and payable within [***] days after CRISPR’s delivery of the applicable report.  
14.3.4.    Following any Opt-Out with respect to an Opt-Out Product, the opting out Party shall, within a reasonable time as mutually agreed by the Parties, (i) transfer to the other Party all Regulatory Filings with respect to such Opt-Out Product, (ii) conduct any technology transfer with respect to such Opt-Out Product as reasonably requested by the non-opting out Party and (iii) use reasonable efforts to transfer to the non-opting out Party any existing relationships with key vendors to the extent relating to such Opt-Out Product. The Expenses of all activities under this Section 14.3.4 shall be shared equally by the Parties.
14.3.5.    If the opting out Party is conducting Manufacturing activities with respect to the Opt-Out Product at the time of such Opt-Out, the opting out Party will continue to supply the other Party’s requirements of the Opt-Out Product, at the other Party’s expense at cost of Manufacturing such Opt-Out Product, until such time as the Parties are able to complete a technology transfer of the applicable Manufacturing technology to the other Party or its designated CMO, and the other Party or such CMO is capable of supplying the other Party’s requirements of the Opt-Out Product. The Expenses of technology transfer activities under this Section 14.3.5, including any Expenses incurred in establishing a CMO capable of Manufacturing the Opt-Out Products, shall be shared equally by the Parties.  
14.3.6.    For the avoidance of doubt, the allocation of [***] and [***] pursuant to Section [***] with respect to an Opt-Out Product shall terminate upon the effectiveness of the Opt-Out for such Opt-Out Product.
14.4.    Consequences of Expiration or Certain Terminations of the Agreement.  If this Agreement expires or is terminated by a Party with respect to one or more Shared Products (each, a “Terminated Product”) in accordance with Section 14.2 at any time and for any reason, the following terms will apply with respect to each Terminated Product: 
14.4.1.    The Parties will return (or destroy, as directed by the other Party) all data, files, records and other materials containing or comprising the other 
59

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Party’s Confidential Information with respect to the Terminated Product, unless such Confidential Information also relates to other products that are subject to the Collaboration Agreement or are necessary for a Party to exercise its rights under Section 14.3. Notwithstanding the foregoing, the Parties will be permitted to retain one copy of such data, files, records, and other materials for archival and legal compliance purposes.
14.4.2.    Termination or expiration of this Agreement for any reason will be without prejudice to any rights or financial compensation that will have accrued to the benefit of a Party with respect to the Terminated Product prior to such termination or expiration. Such termination or expiration will not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.
14.4.3.    Except as may be necessary for a Party to exercise the rights set forth in Section 14.3, all licenses granted by a Party to the other Party under this Agreement with respect to the Terminated Product will terminate and each Party and its Affiliates will cease all Research, Development, Manufacture and Commercialization activities with respect to the Terminated Product.
14.4.4.    Except as may be necessary for a Party to exercise the rights set forth in Section 14.3, Vertex will assign back to the CRISPR Entity designated by CRISPR AG any Patents assigned to Vertex under Section 8.1.3 of the Collaboration Agreement that relate to the Terminated Product to the extent that such Patents do not also relate to other products for which Vertex is retaining an exclusive license under the Collaboration Agreement.
14.4.5.    Except as set forth in Section 14.3, neither Party will have any further rights or obligations with respect to the Terminated Product.
14.5.    Alternative Remedies for Material Breach.  If a Party has the right to terminate this Agreement in its entirety or with respect to one or more Shared Products for the other Party’s material breach pursuant to Section 14.2.2, the non-breaching Party may elect, in lieu of exercising such right, to keep this Agreement in effect, in which case the provisions of Section 14.3 shall apply, [***]%.
14.6.    Survival.  The following provisions of this Agreement will survive any expiration or termination of this Agreement: ARTICLE 1, ARTICLE 7 (with respect to any amounts owed as of the time of expiration or termination or paid during the Co-Co Agreement Term), Section 10.1, Section 10.4, Section 10.6, ARTICLE 11, Section 12.5, Section 12.6, ARTICLE 13, Section 14.3, Section 14.4, Section 14.6, ARTICLE 15, Section 16.1, Sections 16.3-16.18.
60

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

ARTICLE 15
CONFIDENTIALITY

The terms of Article 12 of the Collaboration Agreement will apply with respect to any and all information disclosed by the Disclosing Party to the Receiving Party under this Agreement that meets the definition of Confidential Information under the Collaboration Agreement (including, for clarity, the terms of this Agreement).
ARTICLE 16
MISCELLANEOUS

16.1.    Assignment.  Neither this Agreement nor any interest hereunder will be assignable by either Party without the prior written consent of the other Party, except as follows: (a) Vertex, and subject to Section 16.2, CRISPR, may, subject to the terms of this Agreement, assign its rights and obligations under this Agreement by way of sale of itself or the sale of the portion of such Party’s business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest; provided that such sale is not primarily for the benefit of its creditors; and provided, further, that no CRISPR Entity may assign its rights and obligations hereunder unless all CRISPR Entities are assigning their rights and obligations hereunder to the same Third Party; and (b) either Party may assign its rights and obligations under this Agreement to any of its Affiliates; provided that such Party will remain liable for all of its rights and obligations under this Agreement. An assigning Party will promptly notify the other Party of any assignment or transfer under the provisions of this Section 16.1. This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 16.1 will be void.
16.2.    Change of Control.
16.2.1.    Effects of Change of Control. 
(a)    If during the Co-Co Agreement Term, any CRISPR Entity undergoes a Change of Control to a Competitor, then CRISPR shall [***]. 
(b)    If during the Co-Co Agreement Term, Vertex undergoes a Change of Control to a Competitor, then Vertex shall [***]. 
16.3.    Force Majeure.  Each Party will be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented 
61

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

by Force Majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and the nonperforming Party uses Commercially Reasonable Efforts to remove the condition.
16.4.    Representation by Legal Counsel.  Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the Party that drafted such terms and provisions.
16.5.    Notices.  All notices which are required or permitted hereunder will be in writing and sufficient if delivered personally, sent by nationally-recognized overnight courier or sent by electronic mail, confirmation of receipt requested, addressed as follows:
If to Vertex:
Vertex Pharmaceuticals Incorporated
Attn: Business Development
50 Northern Avenue
Boston, Massachusetts 02110
E-mail: phil_tinmouth@vrtx.com

with a copy to:
Vertex Pharmaceuticals Incorporated
Attn: Corporate Legal
50 Northern Avenue
Boston, Massachusetts 02110
E-mail: paige_goodwin@vrtx.com

and:
Ropes & Gray LLP
Attn: Marc A. Rubenstein
Prudential Tower
800 Boylston Street
Boston, Massachusetts 02199-3600
E-mail: marc.rubenstein@ropesgray.com

If to CRISPR:
CRISPR Therapeutics AG
Attn: Chief Executive Officer
62

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Baarerstrasse 14
6300 Zug
Switzerland
Email: samarth.kulkarni@crisprtx.com

with a copy to:
Goodwin Procter LLP
Attn: Christopher Denn
100 Northern Avenue
Boston, Massachusetts 02210
E-mail: cdenn@goodwinlaw.com

or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice will be deemed to have been given: (a) when delivered if personally delivered on a Business Day (or if delivered or sent on a non-business day, then on the next Business Day); (b) on receipt if sent by overnight courier; or (c) when confirmation of receipt is sent, if sent by electronic mail. Any notices required or permitted under this Agreement that are delivered by Vertex to CRISPR AG pursuant to this Section 16.5 shall be deemed properly delivered hereunder to each of CRISPR UK, CRISPR AG, CRISPR Inc. and Tracr.
16.6.    Amendment.  No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each of Vertex Parent, Vertex UK and CRISPR AG, CRISPR Inc., CRISPR UK and Tracr.
16.7.    Waiver.  No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of Vertex or CRISPR of any breach of any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. Written waiver of any provision of this Agreement by of any one of the CRISPR Entities in accordance with this Section 16.7 shall be binding upon each of CRISPR UK, CRISPR AG, CRISPR Inc. and Tracr.
16.8.    Severability.  If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law.
63

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

16.9.    Descriptive Headings.  The descriptive headings of this Agreement are for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement.
16.10.    Export Control.  This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States of America or other countries that may be imposed upon or related to CRISPR or Vertex from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate Governmental Authority.
16.11.    Governing Law.  This Agreement, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of The Commonwealth of Massachusetts, without regard to conflict of law principles thereof.
16.12.    Entire Agreement.  This Agreement, together with the Collaboration Agreement, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof.
16.13.    Independent Contractors.  Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.
16.14.    Interpretation.  Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include,” “includes” and “including” will be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein,” “hereof” and “hereunder,” and 
64

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Schedules or Exhibits will be construed to refer to Sections, Schedules or Exhibits of this Agreement, and references to this Agreement include all Schedules and Exhibits hereto, (h) the word “notice” will mean notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof and (k) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or.”
16.15.    No Third Party Rights or Obligations.  No provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligations in any Person not a Party to this Agreement.
16.16.    Further Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
16.17.    Counterparts.  This Agreement may be executed in two counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by facsimile or digital transmission (.pdf), each of which will be binding when received by the applicable Party.
16.18.    CRISPR Entities.  Notwithstanding anything to the contrary in this Agreement:
16.18.1.    CRISPR UK, CRISPR AG, CRISPR Inc. and Tracr shall be jointly and severally liable to Vertex for all obligations of CRISPR under this Agreement;
16.18.2.    Breach or violation of any representation, warranty covenant or other obligation of CRISPR under this Agreement may result from, be caused by or arise from the act or omission of any one or more of the CRISPR Entities;
16.18.3.    Any particular right or interest of CRISPR under this Agreement shall only be exercisable once by the first CRISPR Entity to exercise such right or interest hereunder on behalf of CRISPR (i.e., Vertex shall not be liable to more than one CRISPR Entity with respect to any particular 
65

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

right or interest of CRISPR hereunder, including any payment obligations of Vertex hereunder); and
16.18.4.    Any consent or approval of CRISPR permitted or required under this Agreement by any one of CRISPR UK, CRISPR AG, CRISPR Inc. or Tracr shall be binding upon all of the CRISPR Entities.
[SIGNATURE PAGE FOLLOWS]
* - * - * - *

66

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their representatives thereunto duly authorized as of the Effective Date.
						
	VERTEX PHARMACEUTICALS
INCORPORATED
	CRISPR THERAPEUTICS AG
	

By:_/s/ Ian Smith__________________________
Name: Ian Smith 
Title:     Executive Vice President, Chief Operating Officer

	

By:____/s/ Rodger Novak_______________
Name:    Rodger Novak
Title:     President

	VERTEX PHARMACEUTICALS (EUROPE) LIMITED

	CRISPR THERAPEUTICS LIMITED
	By:___/s/ Ian Smith________________________
Name: Ian Smith 
Title: Director

	By:__/s/ Tyler Dylan-Hyde_______________
Name:    Tyler Dylan-Hyde
Title:     Director and Chief Legal Officer

		CRISPR THERAPEUTICS, INC.
		By:__/s/ Rodger Novak_______________
Name:    Rodger Novak
Title:     President

		TRACR HEMATOLOGY LTD.
		By:__/s/ Tyler Dylan-Hyde_______________
Name:    Tyler Dylan-Hyde
Title:     Director and Chief Legal Officer

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule A
[***] ARBITRATION
Selection of [***] Expert and Submission of Positions. The Parties will select and agree upon a mutually acceptable independent Third Party expert who is neutral, disinterested and impartial, and has the experience specified in Section 2.8 for the applicable dispute (the “[***] Expert”). If the Parties are unable to mutually agree upon a [***] Expert within [***] days following the delivery of the request for [***] Arbitration, then upon request by either Party, the [***] Expert will be an arbitrator appointed by Judicial and Mediation Services (“JAMS”), which arbitrator need not have the above-described experience. Once the [***] Expert has been selected, each Party will within [***] days following selection of the [***] Expert provide the [***] Expert and the other Party with a written report setting forth its position with respect to the substance of the dispute and may submit a revised or updated report and position to the [***] Expert within [***] days of receiving the other Party’s report. If so requested by the [***] Expert, each Party will make oral submissions to the [***] Expert based on such Party’s written report, and each Party will have the right to be present during any such oral submissions.
JAMS Supervision. In the event the [***] Expert is a JAMS arbitrator selected by JAMS as provided in this Schedule A, the matter will be conducted as a binding arbitration in accordance with JAMS procedures, as modified by this Schedule A (including that the arbitrator will adopt as his or her decision the position of one Party or the other, as described below). In such event, the arbitrator may retain a Third Party expert with the same experience specified in Section 2.8 for the [***] Expert to assist in rendering such decision, and the expenses of any such expert will be shared by the Parties as costs of the arbitration as provided in this Schedule A.
Determination by the [***] Expert. The [***] Expert will, no later than [***] days after the last submission of the written reports and, if any, oral submissions, select one of the Party’s positions as his or her final decision, and will not have the authority to modify either Party’s position or render any substantive decision other than to so select the position of either Party as set forth in their respective written report (as initially submitted, or as revised in accordance with this Schedule A, as applicable). The decision of the [***] Expert will be the sole, exclusive and binding remedy between them regarding the dispute submitted to such [***] Expert.
Location; Costs. Unless otherwise mutually agreed upon by the Parties in writing, the in-person portion (if any) of such proceedings will be conducted in Boston, Massachusetts. [***]
Timetable for Completion in [***] Days. The Parties will use, and will direct the [***] Expert to use, commercially reasonable efforts to resolve a dispute within [***] days after the selection of the [***] Expert, or if resolution within [***] days is not reasonably achievable, as determined by the [***] Expert, then as soon thereafter as is reasonably practicable

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule B
Reserved

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule C-1
PROJECT TEAM FUNCTIONS

			
	Functions on Project team

	[***]

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule C-2
INITIAL PROJECT TEAM MEMBERS
[***]

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule D
INITIAL CLINICAL TRIALS
[***]

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule E
CRISPR IN-LICENSE AGREEMENTS

[***]

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule F
VERTEX IN-LICENSE AGREEMENTS
[***]

74 

 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. 

Schedule G
CRISPR DISCLOSURE SCHEDULE
[***]

75

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]